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Despite considerable effort considerable cost in both time and money, as many as 
two out of three persons with type 1 diabetes are not in control of their disease.  As a 
result, 40% of these individuals will go on to develop at least one serious complication 
including retinopathy, nephropathy, neuropathy and cardiomyopathy.  It is further 
estimated that as much as $4 billion could be saved annually if all persons with type 1 
diabetes in the US were properly controlled. 
Adequate treatment of type 1 diabetes is predicated on the estimation of three 
clinical insulin therapy parameters: the basal dose, the insulin sensitivity factor and the 
insulin-to-carbohydrate ratio.  Currently, these therapy parameters are determined by 
iterative titration procedures based on expert opinion.  Unfortunately, there is evidence 
suggesting that for the majority of individuals, these titration protocols do not provide 
good results. 
In this work we develop an alternative to traditional insulin titration protocols that 
allows clinical insulin therapy parameters to be estimated directly from a set of easily 
acquired measurements. 
First, a simple model of type 1 diabetes is used to derive a series of equations 
connecting the model’s parameters to the clinically important insulin therapy parameters 
 vi 
of insulin sensitivity factor, insulin-to-carbohydrate ratio and basal insulin dose.  The 
simplifying assumptions used to derive these equations are tested and shown to be valid 
and the Fisher Information Matrix is used to demonstrate parameter identifiability.   
Parameter estimation is then performed on two cohorts of virtual subjects, as well 
as two segments of real continuous glucose monitoring data from a person with type 1 
diabetes.  Identification of the true insulin therapy parameters is successful under most 
conditions for both cohorts of virtual subjects.  Parameter estimation for one of the two 
segments of real continuous glucose monitoring data is also successful. 
Finally, because continuous glucose monitors are instrumental to successful 
implementation of our insulin therapy framework, the physiological environment in 
which continuous glucose monitoring takes place is modeled and a fundamental 
limitation on measurement precision is shown to exist.  An examination of physiological 
variability in the parameters indicates that many of the challenges observed in real world 
continuous glucose monitoring may have a relationship to changes in capillary bed 
perfusion.  A rationale for anecdotally reported sensor faults is also proposed based on 
the physical mechanisms explored. 
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Chapter 1: Introduction 
Type 1 Diabetes Mellitus (T1DM), is an autoimmune disorder that affects over 
1,000,000 individuals in the US, resulting in the destruction of the insulin-producing cells 
of the pancreas. Currently, the annual cost of T1DM in the US is $14.4 billion with $6.9 
billion being spent on direct treatment costs and an additional $7.5 billion incurred as 
indirect costs [1].  Despite the considerable resources devoted to treating T1DM, more 
than 66% of Americans with T1DM fail to meet the American Diabetes Association’s 
(ADA) standard for good control [2], [3].  As a result, countless individuals develop 
serious complications including retinopathy, nephropathy, cardiomyopathy, neuropathy 
and vascular disease [4].  As an example of the prevalence of these complications, as 
many as 30% of individuals with T1DM will develop full or partial blindness and as 
many as 40% will develop peripheral neuropathy which can lead to lower limb 
amputation [2]. 
INTENSIVE INSULIN THERAPY AND TITRATION 
Forestalling or even preventing the development of these complications is 
possible by maintaining adequate glucose control.  Two landmark studies, the Diabetes 
Control and Complications Trial (DCCT) [5] and the follow-up Epidemiology of 
Diabetes Intervention and Complications (EDIC) study [6] showed that intensive insulin 
therapy, with the goal of approaching near normal glycemia, significantly reduces the risk 
of nearly all diabetes related complications. 
Presently, intensive insulin therapy involves the determination of three clinical 
therapy parameters.  These parameters are: the basal insulin dose, which is the amount of 
long-acting insulin needed to ensure fasting euglycemia, the insulin sensitivity factor, 
which is the decrease in blood glucose following the injection of a single unit of rapid-
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acting insulin and the insulin-to-carbohydrate ratio which is the dose of rapid-acting 
insulin needed to cover a specific number of carbohydrates [7]. 
Determining these clinical therapy parameters involves a process of titration 
wherein the appropriate dose of insulin is gradually determined through trial and error.  
The general approach to titration is to initiate therapy and then use a schema or algorithm 
to adjust the three insulin therapy parameters to reach a selected glycemic target.  Some 
of these algorithms, such as the insulin titration protocol from the ADAPT trial [8] shown 
in Figure 1-1, clearly spell out what actions are to be taken under what circumstances.  
For example, given the ADAPT titration algorithm, if an individual has a fasting glucose 
value that exceeds 180 mg/dL, the protocol recommends that the dose of long-acting 
basal insulin be increased by 6 U.  Other algorithms, such as the Insulin Algorithm for 
Type 1 Diabetes Mellitus in Children and Adults shown in Figure 1-2, provide glycemic 
guidelines, but do not recommend a specific action.  In these cases, it is left to the 
physician to use his judgment when adjusting insulin therapy.  A review of the literature 
reveals that while there are many guidelines for titration there does not appear to be a 
consensus on which algorithm is best.  This is problematic because different titration 
algorithms can produce different therapy recommendations [9].  In addition, even for 
well-defined titration protocols such as the one used in the ADAPT titration algorithm 
[8], physicians often use their own judgment when adjusting insulin therapy. 
Another significant problem is the convergence of these titration algorithms to a 
good treatment result.  Because titration decisions often take place at intervals of three to 
six months, convergence of the algorithm to a good set of clinical therapy parameters 
may take an unacceptable amount of time.  More problematically, because each algorithm 
is based on expert opinion, there is no guarantee that the algorithm will ever converge.  
This issue has been borne out by several clinical trials involving titration algorithms 
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where good control was achieved in only 14%, 25%, 32% and 38% of persons with 
T1DM following 28 weeks, 26 weeks, 52 weeks and 104 weeks respectively [8], [10]–
[12]. 
CURRENT EFFORTS TO REPLACE OR IMPROVE INSULIN TITRATION 
Several approaches have been taken to improve clinical outcomes for the many 
individuals with poorly controlled T1DM.  Among these alternatives are those that 
augment or supplement titration and those that propose a new treatment paradigm or 
otherwise replace titration. 
One augmentation to traditional insulin titration algorithms makes use of a tool 
called the ambulatory glucose profile (AGP) [13]–[15].  Discussed as far back as 1987, 
the ambulatory glucose profile is essentially a visualization tool that allows health care 
providers to more easily identify temporal patterns in an individual’s blood glucose.  
When initially developed, the AGP was created using data from traditional glucometer 
readings.  This required individuals to take four readings per hour each day over the 
course of 14 days [13].  By plotting these measurements a physician is able to observe 
blood glucose patterns and make insulin therapy adjustments accordingly.   
At the time, this approach was limited by the fact that few patients are likely to 
adhere to such an intensive measurement schedule as well as by the need for equal or 
greater physician skill than required by traditional titration protocols.  The availability of 
continuous glucose monitors has made the measurement burden less onerous, for the 
AGP as well as similar visualization techniques, but physician skill is still required to 
interpret the large volume of data [14], [16].  In addition, because the AGP is a tool to 
supplement physician decisions and not replace traditional titration, the length of time 
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needed to achieve good control may still be prohibitive assuming a three to six month 
delay between insulin adjustments. 
In contrast, one replacement or substitute for traditional titration is closed-loop 
insulin delivery.  Sometimes described as an artificial pancreas, closed-loop insulin 
delivery systems use continuous subcutaneous insulin infusion as well as continuous 
glucose measurements to automatically regulate blood glucose levels.  A recent search on 
ClinicalTrials.gov for the term “artificial pancreas” reveals that at present, work on 
closed-loop insulin therapy is in an advanced state with 15 completed clinical trials, four 
clinical trials currently underway and 28 clinical trials in preparation.  Further, in remarks 
made during the 2012 Barbara Davis Center Keystone Conference, John Pickup, MD 
(King’s College London School of Medicine) indicated that both pumps and closed-loop 
algorithms are sufficiently optimized for closed-loop control [17].   
However, in these same remarks Dr. Pickup highlights that the availability of 
reliable glucose sensing and improved insulin analogues currently limit the success of 
closed-loop insulin control [17].  In addition to these technical hurdles, the regulatory 
path for closed-loop insulin control is unclear and likely to be burdensome and 
development costs will likely exceed $170 million [17].  Further, even following 
regulatory approval, cost-effectiveness may still plague reimbursement, as it did with the 
continuous glucose monitor [18].  Finally, some individuals may be unwilling to switch 
to pump therapy because of personal preference or for psychosocial reasons.  As it stands, 
insulin pumps are used by only 13% - 40% of persons with T1DM in the US and 5% - 
15% of persons with T1DM in Europe [19], [20]. 
A third alternative that straddles the line between augmenting and replacing 
traditional titration algorithms is the decision support system.  The development of new 
tools including decision support systems and clinical informatics has been identified as 
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one way to improve the outcomes of individuals with T1DM by several authors including 
those of the landmark Diabetes Attitudes, Wishes and Needs (DAWN) study [21], [22].   
In principle, decision support systems can address the challenge of titration by 
lowering the requirement for provider skill and by allowing a physician to spend less of 
their already limited time pouring over an individual’s recorded blood glucose 
measurements, a prerequisite for titrating insulin therapy [17]. 
Presently, at least one commercial decision support system for insulin titration, 
the Diabetes Insulin Guidance System (Hygeia, Inc., Ann Arbor, MI), is in development 
[23]. The Diabetes Insulin Guidance System is built on an algorithm that is intended to 
mimic the insulin titration recommendations of a skilled physician [23].  As a result, 
individuals with diabetes get the benefit of physician-led titration, but without the typical 
three to six month delay between titration decisions.  However, this particular 
implementation of decision support would still suffer from the other shortcoming of 
titration, namely its inability to provide good control for as many as 62% of persons with 
T1DM [11]. 
Regardless of which approach is taken, successful replacement or improvement of 
current titration protocols would yield tremendous human and economic benefits.  
Looking at the human element, it is estimated that 920,000 additional years of eyesight, 
691,000 additional years of kidney health and 678,000 additional years without lower 
limb amputation would result from universally good control of T1DM [22].  In addition, 
despite an increase in certain upfront costs, the total direct and indirect treatment costs for 
properly treated T1DM could drop by 8% and 50% respectively, yielding an annual 
savings of $4 billion in the US [1], [22]. 
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RESEARCH OBJECTIVES 
The overall goal of this work was to develop a novel method for estimating and 
personalizing clinical insulin therapy parameters.  This method would form the basis for a 
decision support system that does not hew to existing insulin titration protocols.  The 
ideal properties of this system include: 
 
1. The ability to make good insulin therapy recommendations for most 
patients in a short time window—e.g., in a single physician visit as 
opposed to ten physician visits. 
2. Little or no specialized training requirements for either physicians or 
patients. 
 
To develop this system, the following approach was taken: 
 
1. Select the simplest adequate model of T1DM and use it to derive closed-
form expressions for the ideal basal dose, insulin sensitivity factor and 
insulin-to-carbohydrate ratio. 
2. Analyze the model and these derived equations to evaluate both the 
uniqueness and the uncertainty of the insulin therapy parameters. 
3. Demonstrate that the selected model can characterize the dynamics of 
T1DM and that the parameters in these closed-form expressions for ideal 
basal dose, insulin sensitivity factor and insulin-to-carbohydrate ratio can 
be accurately identified from simple experiments. 
4. Evaluate whether likely measurement errors will introduce unacceptable 
variation or bias in the estimated insulin therapy parameters. 
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GUIDE TO CHAPTERS 
Because this work may be of interest to both engineers and health care 
professionals, two separate chapters on background were included.  In Chapter 2, we 
discuss the pathology, epidemiology and treatment of diabetes for those who are 
unfamiliar with the condition.  In Chapter 3, we give a general exposition of the 
mathematical techniques used in this research which may be of interest to those without a 
background in mathematics and systems modeling.  In Chapter 4, we derive the insulin 
sensitivity factor, insulin-to-carbohydrate ratio and basal insulin dose from the Bergman 
Minimal Model and consider both the uniqueness and uncertainty of these therapy 
parameters.  In Chapter 5, we show that accurate estimates of these therapy parameters 
can be derived using self-reported meal and insulin logs and continuous glucose 
measurements.  We also demonstrate that the model and insulin therapy framework 
proposed in Chapter 4 can be used to accurately estimate the insulin therapy parameters 
for much more complicated models of diabetes as well as real human data.  In Chapter 6, 
we study the biology of the skin and determine whether physiological variations in 
subcutaneous glucose concentrations introduce unacceptable measurement errors to the 
required continuous glucose measurements.  Finally, we close with Chapter 7 which 
includes conclusions and future work. 
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Figure 1-1: Titration Protocol from the ADAPT Trial  
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Figure 1-2: Titration Guidelines from the Texas Diabetes Council 
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Chapter 2: Physiological Background 
In healthy individuals, cellular uptake and disposition of glucose, the primary 
substrate involved in cellular respiration, is controlled by a system of regulatory and 
counter regulatory hormones.  Chief among these hormones is insulin which is produced 
in the beta cells of the pancreas.  In diabetes, glucose metabolism is impaired by the 
body’s inability produce insulin—as in type 1 diabetes mellitus (T1DM)—or by the 
body’s insensitivity to insulin—as in type 2 diabetes mellitus (T2DM). 
Below we will review the basic hormonal control which governs human glucose 
uptake.  This will allow us to more clearly distinguish between the two primary varieties 
of Diabetes Mellitus, the pathology, prevalence and economic consequences of which are 
also discussed.  Lastly, we will review the action and history of glucose measurement 
devices as well as insulin and insulin delivery devices. 
GLUCOSE METABOLISM 
All living things must eat to survive.  In humans, digestion begins with salivary 
amylase, continues with action of gastric enzymes in the stomach and concludes with 
both pancreatic and natively secreted enzymes in the small intestine.  The result is that 
proteins, fats and carbohydrates are digested or broken down into small peptides, fatty 
acids and monosaccharides and absorbed in the small intestine.   
Utilization of these nutrients requires: bulk transport and diffusion to a given 
cellular surface, active or passive transportation across the cellular membrane and finally 
various transformations performed by a given cell’s internal machinery.   
Hormones control nearly every process in the body, including the regulation of 
nutrient supply and metabolism [1].  Cellular uptake of glucose is controlled primarily by 
insulin, produced by specialized beta cells located in the pancreas [2].  Insulin exerts its 
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influence by increasing the proportion of GLUT4—the primary glucose transport protein 
found in humans—present on a given cell’s surface [3].  Glucose transport into the cell is 
followed rapidly by either utilization in ATP synthesis or storage as either glycogen in 
the skeletal muscles and liver or as fat in adipose tissue [4].  In mammals, up to 90% of 
all glucose metabolism is mediated and controlled by insulin, taking place in the skeletal 
muscles (75%) and adipose tissue (5-15%) [4].  Further, as transport across the cell 
membrane is the rate-limiting step in glucose utilization—except in the case of very high-
levels of glucose utilization as might occur with vigorous physical activity—insulin is of 
singular importance in regulating the body’s glucose levels [3].  
Counterbalancing the action of insulin are both rapid-acting hormones, which 
include the catecholamines and glucagon, as well as slow-acting hormones which include 
cortisol and growth hormone [1], [5].   
Among these hormones, glucagon is the clearest antagonist to insulin, increasing 
plasma glucose concentrations by stimulating glycogenolysis and gluconeogenesis in the 
liver [6].  The catecholamines act by suppressing the release of insulin, stimulating 
hepatic and renal gluconeogenesis, inhibiting peripheral glucose utilization and 
promoting the formation of ketone bodies, which can be used by the brain for energy, via 
lipolysis [5], [7].  Unlike glucagon and the catecholamines, which act to prevent acute 
hypoglycemia, cortisol and growth hormone are important in maintaining euglycemia 
during prolonged fasting [7].  Both cortisol and growth hormone act by promoting 
gluconeogenesis and lipolysis with growth hormone also suppressing peripheral glucose 
utilization. 
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DIABETES 
Diabetes is a dysfunction of the body’s glucoregulatory system.  The two most 
prevalent forms of diabetes are T1DM and T2DM.   
T1DM is an autoimmune disease of uncertain cause which typically results in a 
complete inability to produce insulin.  T2DM by contrast is a disease of insulin 
resistance, wherein normal pancreatic function is initially maintained, but cellular 
sensitivity and responsiveness to insulin are diminished.  For both diseases, severe long-
term complications include coronary artery disease, peripheral vascular disease, stroke, 
cardiomyopathy, nephropathy, neuropathy and retinopathy [1]. 
As a note on nomenclature, in the past, T1DM has been referred to as both 
juvenile-onset diabetes or insulin-dependent diabetes mellitus (IDDM), while T2DM has 
sometimes been described as either adult-onset diabetes or noninsulin-dependent diabetes 
mellitus (NIDDM).  However, because both T1DM and T2DM can develop in either 
children or adults and because both T1DM and T2DM can be treated with insulin, these 
other names have begun to fall into disuse.   
Type 1 Diabetes Mellitus 
T1DM is the result of the autoimmune destruction of the insulin-producing beta 
cells of the pancreas [8].  Individuals begin to develop the obvious signs of T1DM 
following the destruction of 80% - 90% of the beta cells [8].  The destruction of the 
insulin-producing cells is absolute in most persons with diabetes, though limited beta cell 
function has been observed in some of the longest surviving persons with diabetes [9].  
However, even in individuals with some residual beta cell function, in the absence of 
exogenous insulin, those with symptomatic T1DM will soon die as a result of diabetic 
ketoacidosis (DKA) [10]. 
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In addition to preventing DKA, intensive insulin therapy, defined as treatment 
with the goal of achieving euglycemia or near-normal glycemia, has been shown to 
significantly reduce the risk of the long-term complications associated with T1DM [11].  
The landmark Diabetes Control and Complications Trial (DCCT) [12] and follow-up 
Epidemiology of Diabetes Intervention and Complications (EDIC) study [13] showed 
that risks of retinopathy, nephropathy, neuropathy and cardiovascular disease could be 
reduced by as much as 76%, 50%, 60% and 57% respectively.   
As of 2007, T1DM affected 850,000 – 1,700,000  individuals in the United States 
with an estimated direct medical cost of $6.9 billion and an estimated indirect cost of 
$7.5 billion [14]. 
Type 2 Diabetes Mellitus 
By contrast, T2DM is a disease of insulin insensitivity.  T2DM is also 
significantly more common than T1DM, affecting between 16 and 18 million individuals 
in the United States in 2012, and having a total treatment cost of $245 billion [15]. 
Most individuals initially present as obese or overweight and as a result the first-
line therapy in T2DM is typically lifestyle changes, such as changes in diet and exercise 
[16].  While some individuals are able to halt the progression or even reverse the course 
of their disease through lifestyle changes, often oral drug therapy must be initiated to 
maintain control of the disease.  However, if hyperglycemia cannot be controlled, insulin 
therapy is recommended by the American Diabetes Association [17].   
GLUCOSE MEASUREMENT 
In T1DM and T2DM treated with intensive insulin therapy the regular 
measurement of blood glucose levels, typically upon waking and before meals, is a 
crucial element in disease management [18].  The purpose of these measurements is to: 
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record data upon which health care providers can make therapy decisions for a patient,  
inform treatment decisions that may be flexible, such as adjusting the amount of insulin 
to be administered before a meal, detect hypoglycemia or hyperglycemia and provide 
immediate feedback to a patient about the effect of their lifestyle choices [19]. 
The most common tool for measuring blood glucose is the glucometer, which 
measures the concentration of glucose in a small blood sample—obtained with a lancet—
electrochemically [20].  Outcomes in both T1DM and T2DM are generally better among 
patients who measure their blood glucose more frequently, though regular measurement 
is more important among insulin-treated persons with diabetes as both a means of making 
insulin dosing decisions and detecting hypoglycemia [19].   
In addition to the discrete measurements provided by glucometers, continuous 
glucose measurements can be made using a continuous glucose monitoring (CGM) 
device.  Presently, CGM devices are marketed by Abbott Diabetes Care, DexCom and 
Medtronic, though Abbott does not presently sell CGM systems in the US.  Initial 
forecasts suggested that as many as 160,000 persons with diabetes in the US would be 
using continuous glucose monitors by 2009 [21].  However, due to issues with 
reimbursement and a lack of education among both patients and health care providers, 
adoption has been limited, with the total global user base in 2013 being 16,000 – 19,000 
persons with diabetes [22], [23]. 
An important and related glycemic indicator used in the management of both 
T1DM and T2DM is that of A1C.  A1C—sometimes referred to as HbA1c—is the 
percent glycosylation of hemoglobin in a sample of blood.  Increasing blood glucose 
concentrations result in increased hemoglobin glycosylation and given the lifespan of 
hemoglobin, A1C is a proxy for average glycemia over the preceding 2 - 3 months [11].  
High A1C has been linked to the development of long-term complications and is the 
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means de rigueur of assessing whether an individual’s diabetes is properly controlled 
[11], [12].  In healthy individuals, A1C typically ranges between 4% - 6%, whereas per 
the ADA, a person with diabetes is considered in control if his or her A1C is below 7% 
[17].   
INSULIN 
Insulin was first discovered in 1922 by Frederick Banting, who went on to win the 
Novel Prize for his discovery [10].  The earliest commercial insulins were derived from 
the pancreatic extracts of various animals and while capable of preventing DKA, their 
clearance from the plasma was too rapid to provide good glycemic control [10].  It was 
not until 1946, when chemists at Nordisk were able to develop neutral protamine 
Hagedorn (NPH) or isophane insulin, the first intermediate-acting insulin, that good day-
long control was possible [10].  Further refinement of NPH insulin, specifically the 
addition of zinc crystals to delay absorption from the subcutaneous injection site,  
produced the first long-acting insulins, lente and ultralente insulin [10].   
Following the development of longer acting insulins, therapy moved in the 
direction of so-called basal/bolus protocols.  The overall goal of basal/bolus protocols 
was to mimic physiological insulin levels seen in healthy individuals.  This approach to 
insulin therapy called for a low baseline concentration of insulin to maintain fasting 
euglycemia with larger postprandial concentrations to prevent hyperglycemia following a 
meal [24].  This could be achieved by using either a mixture of rapid-acting regular 
insulin and NPH insulin immediately before a meal or by using a combination of long-
acting ultralente once-daily with rapid-acting regular insulin being administered with 
each meal [24].   
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With the advent of recombinant insulin made by bacteria, the pharmacokinetics of 
insulin could be modified directly by making changes to the protein’s sequence as 
opposed to indirectly through pH modifications or the addition of zinc as was done with 
NPH, lente and ultralente [24].  As a result regular human insulin has been largely 
replaced by insulin lispro—brand name Humalog—and insulin aspart—brand name 
Novolog—where rapid-acting insulin is appropriate and ultralente has been replaced by 
insulin glargine—brand name Lantus—and insulin determir—brand name Levemir.   
While there has been some criticism of these newer analogues, suggesting that 
they cost significantly more than the drugs they replace without improving patient 
outcomes, it is at the very least agreed that they make treatment more convenient, 
especially in T1DM where multiple-daily injections of insulin are required [10], [25]. 
Insulin Administration Devices 
Administration of insulin can be done with either a syringe or a pre-loaded pen.  
Insulin pens are available with a wide range of insulins and are generally preferred by 
patients as they are easier to use and less intimidating than a syringe [26].  This 
preference also results in improved adherence, better patient outcomes and lower total 
treatment costs [27].  
As with glucose measurement, insulin administration can be done either discretely 
as with syringes and pens or continuously with a pump.  There is conflicting evidence as 
to the advantage of insulin pumps—providing continuous subcutaneous insulin infusion 
(CSII)—over pens and syringes—used to provide multiple daily injection (MDI) 
therapy—with some studies suggesting there is no difference in outcomes [28] and others 
suggesting that CSII therapy provides a slight advantage over MDI therapy with respect 
to both A1C levels and the risk of hypoglycemia [29].   
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The annual treatment cost for insulin pump therapy is about the same as that of 
insulin pen therapy, averaging near $3,200 excluding the upfront cost of around $5,000 
for the pump itself [28].  The use of syringes for MDI therapy is significantly less 
expensive at around $1,200 per year, but the benefit of improved patient adherence 
provides an indirect economic benefit, which exceeds the direct price difference [27], 
[28].   
Despite the variety of drugs and devices available to treat both T1DM and T2DM, 
in aggregate, the evidence seems to suggest that highly motivated patients have good 
outcomes regardless of the type of insulin that they use or the method of administration 
[10], [30]. 
SUMMARY 
Diabetes is a disease of the glucoregulatory system which either necessitates—as 
in T1DM—or often requires—as in T2DM—treatment with insulin.  The goal of insulin 
therapy is to induce near-normal glycemia by mimicking the action of a healthy pancreas.  
Typically this entails the administration of a long-acting insulin analogue to produce so 
called basal control as well as various rapid-acting analogues to offset the effect of meals 
or other disturbances, such as illness or stress.  Regular measurements of blood glucose 
concentrations with a glucometer are also required to monitor the body’s response to 
meals and insulin so as to adapt therapy and detect hypoglycemia.   
Avoiding the development of long-term complications, including damage to the 
heart, vasculature, kidneys, peripheral nervous system and eyes, is possible if average 
blood glucose concentrations are sufficiently close to those seen in healthy individuals.  
The trade-off being that intensive therapy, designed to produce near-normal glycemia, 
significantly increases the risk of iatrogenic hypoglycemia. 
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Chapter 3: Mathematical Preliminaries 
For those with backgrounds primarily in health care, we review some of aspects 
of pharmacokinetic (PK) and pharmacodynamic (PD) modeling as well as parameter 
estimation and epidemiological modeling.  Readers who are familiar with these concepts 
may skip directly to subsequent chapters where the specific details of the present work 
will be discussed in depth. 
PHARMACOKINETIC AND PHARMACODYNAMIC MODELING 
Pharmacokinetic modeling is concerned with the absorption, distribution, 
metabolism and elimination of drugs and other compounds in the body, whereas 
pharmacodynamic modeling deals with the effects of these drugs on various biological 
processes [1].  By understanding how the discrete administration of a given drug affects 
the dynamic concentration of said drug and its metabolites, practitioners are able to 
screen new drugs for potential toxicity, extrapolate between animal and human models, 
ascertain what a typical dose should be and adjust drug regimens to account for 
complicating factors such as decreased kidney function or co-administration of 
interacting drugs [2].  As a result, PK/PD modeling is important to pharmaceutical 
chemists, health care professionals and patients. 
Generally, PK modeling is somewhat separate from PD modeling as it is easier to 
measure the concentration of a drug than its effect.  PK modeling is approached from one 
of several avenues including: compartmental modeling, noncompartmental modeling, 
physiological modeling or population modeling, depending on the drug in question and 
the aims of the researcher [1].   
In compartmental modeling, one hypothesizes that a drug is distributed 
throughout a series of compartments.  Linear ordinary differential equations are typically 
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used to describe a mass balance across these compartments, which means that the 
connection between dose size and observed concentration will be a sum of exponentials. 
Noncompartmental modeling looks at information that can be derived directly 
from the data and treats these measurements as outputs of the administered dose.  
Examples of the modeled outputs of a noncompartmental model include: area under the 
curve for a time series of concentration measurements, the maximum drug concentration 
for a given dose and the time required to reach this maximum concentration.  This type of 
modeling is often used to show bioequivalence between two formulations of the same 
active pharmaceutical ingredient as is required for the FDA approval of some generic 
drugs. 
Physiologically-based pharmacokinetic (PBPK) models are similar to 
compartmental models with the exception that each compartment corresponds to a tissue, 
organ system, cellular site or other physiologically meaningful location within the body. 
PBPK models are advantageous in that they can be used to answer important 
physiological questions including for example, the effect of decreased renal clearance or 
lung capacity on the concentration and effect of a drug throughout the body.  PBPK are 
however more difficult to develop and validate than compartmental models as they 
typically require measurements of drug concentration throughout the tissues being 
modeled or the cobbling together of sub-models of each organ system from the literature.  
Further, collecting the data required to develop a PBPK model may require 
uncomfortable measurement procedures—including the measurement of exhaled gases or 
the performance of tissue biopsies—or the administration of radio-labeled drugs. 
Lastly, population PK models essentially pool together the PK data from several 
subjects to understand how each model parameter is distributed across a population.  This 
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kind of analysis can be very important when determining appropriate dosages for a novel 
pharmaceutical compound. 
Mapping drug concentrations to drug effects is done by linking a PK model to a 
PD model.  Generally, this is done by either appending an effect compartment to the 
dynamic PK model or by modeling the effect as a static nonlinear function of the drug 
concentration in one of the PK compartments [1].  If an effect compartment is to be used, 
the assumption of first order linear kinetics often holds, though nonlinear models are 
common and include Hill kinetics or Michaelis-Menten kinetics [1].    
IDENTIFIABILITY AND PARAMETER ESTIMATION 
The problem of parameter estimation is in some sense three-fold.  First, for a 
given model structure is there any set of inputs and observations that allow one to 
uniquely identify the values of each model parameter.  This is known as the problem of 
structural identifiability. Second, given the particular set of inputs and observations for 
which you have collected data, is it possible to uniquely identify the values of each model 
parameter.  This is known as the problem of informational identifiability and is closely 
related to so-called persistency of excitation.  Finally, given the errors in your data and 
your computational resources is it possible for you to numerically estimate the values of 
these model parameters.  This is what is typically thought of as parameter estimation or 
the inverse problem. 
The general theory of identifiability, describing the necessary and sufficient 
conditions for both structural and informational identifiability, is well-developed.  The 
following outline is adapted from Ljung et al. [3] 
Let us consider the typical state-space model: 
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                           (3.1)  
   
                      (3.2)  
 
Where x corresponds to some unobserved states, u corresponds to known inputs, y 
corresponds to known measurements and θ is the vector of parameters we would like to 
estimate. 
By definition, if this model is structurally identifiable given some set of inputs u 
and some initial condition xo, the outputs y will be differ for each parameter vector θ. 
More formally, if a model is structurally identifiable the following statement is true:  
 
                                         (3.3)  
 
where P is the space of all possible parameter values.  
A necessary and sufficient condition for the structural identifiability of our model 
is given by: 
 
                              (3.4)  
 
where Pi and Qi are functions of only u and y formed by differentiating, adding and 
subtracting or scaling and multiplying the combined set of Equations 3.1 and 3.2 and θi is 
the i
th
 element of the d-dimensional vector θ.  Equation 3.4 also serves as a necessary and 
sufficient condition on informational identifiability, namely, a set of inputs u producing 
outputs y is persistently exciting if and only if Pi is non-zero for all i. 
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Actually verifying that Equation 3.4 holds for a given model system is normally a 
very difficult task except.  When dealing with biological systems this is doubly true as 
many of the body’s states are difficult or impossible to observe and to increase the 
robustness of an organism biological systems exhibit a large amount of redundancy [4], 
[5].  In principle, the question can be answered by one of several methods including the 
Taylor Series approach, the Generating Series approach, the Similarity Transform 
approach or the Differential Algebra approach [6].  However, even in the case of linear 
compartmental models, each of these approaches requires the symbolic solution of 
complex nonlinear equations and if possible it is preferable to work with one of the 
families of models for which proofs about identifiability exist [7]. 
Once the identifiability of a model has been established parameter estimation 
techniques are used to identify the values of θ by minimizing some objective function of 
the parameters, typically, the sum of square errors: 
 
                   
 
 
 
    (3.5)  
 
 
where yobs is the measured output and       is the solution to Equation 3.2. 
Due to measurement noise, the surface J(θ) is typically rough and finding the 
parameter vector θ that would otherwise be the global minimizer may be challenging.  In 
addition, as posed each iterative solution of J(θ) will require numerical integration of 3.1 
and 3.2 making this problem computationally intensive. 
One way to sidestep some of the challenges described above is by using a 
technique called principal differential analysis (PDA).  In PDA, one fits a basis function 
to the data, typically a spline, and then uses this basis function to calculate the derivatives 
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directly [8], [9].  As a result, if all the states in Equation 3.1 are observed—i.e. if y = x in 
Equation 3.2—one can minimize the following in place of Equation 3.5: 
 
                      
  
 
    (3.6)  
 
While the ability to observe every state, especially in a biological system may 
seem restrictive, we will see that for some models of diabetes this requirement can be 
satisfied.   
EPIDEMIOLOGICAL MODELING 
According to the WHO, epidemiology is the study of the distribution and 
determinants of health-related states or events.  Epidemiological modeling gives us a way 
to map the effect of drug therapies or other interventions at the individual level to the 
development of long-term complications. 
Epidemiological modeling requires first that we have a PK/PD model for a given 
disease.  We next must assume or otherwise determine the population level distribution of 
the parameters governing our model.  Combining these two models allows us to evaluate 
how a given treatment policy, e.g. the administration of a 300 mg of a drug three-times 
daily, will effect a simulated patient population.  We next need a risk model that links 
either the outputs of the PK/PD model or some transformation thereof, e.g. average HDL 
levels over a given time interval, to the development of various disease states.   For 
comparison of some drug therapies this may be sufficient, especially where there is one 
dominant complication the therapy is designed to prevent.  However, in the case of a 
disease with several severe complications such as diabetes, it is also helpful to have an 
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economic model that will allow us to calculate the expected loss associated with different 
complication profiles across compared therapies. 
Epidemiological modeling of this kind is already prevalent in determining 
reimbursement for drug therapies [10], replacing animal trials [11] and designing 
subsequent human trials [12]. 
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Chapter 4: Treatment Decisions from Mathematical Models of Diabetes 
Mathematical modeling of the glucoregulatory system has been an active area of 
research for over forty years [1]–[3].  The majority of work done by the controls 
community has focused on the development of closed-loop control with insulin pumps, 
referred to as the artificial pancreas.  Despite being an important area of research, among 
persons with T1DM, pump adoption has been limited in both the US and Europe.   
As a result, there is a clear need to connect existing models of diabetes with the 
treatment parameters used by someone on MDI therapy.  These treatment parameters are 
the basal insulin dose, the insulin sensitivity factor (ISF)—which is the drop in blood 
glucose caused by a unit of rapid-acting insulin—and the insulin to carbohydrate ratio 
(I2C)—which governs the amount of insulin needed to prevent post-prandial 
hyperglycemia [4]. 
In this chapter we derive a simple control law based on the eponymous Bergman 
Minimal Model (BMM) [5].  The accuracy, limitations and underlying assumptions of 
this control law are discussed and a connection between the clinical MDI parameters of 
basal dose, ISF and I2C is made.  The Fisher Information Matrix (FIM) is used to 
establish a posteriori identifiability of the model under home-use conditions.  Lastly, the 
sensitivity of the controller to both parameter and input uncertainty is discussed. 
MODELING ENVIRONMENT 
Bergman Minimal Model  
The BMM was first proposed for the purposes of modeling glucose disappearance 
following an intravenous glucose tolerance test (IVGTT).  It was originally described as a 
two compartment model, with one compartment (G) describing the concentration of 
glucose in the plasma and a second (X) describing the remote action of insulin.  As 
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formulated however, there is an implicit third compartment corresponding to the plasma 
insulin (I).  Here we have also included a term corresponding to the mass of 
carbohydrates in the gut (Ggut) allowing us to model the effect of meals on blood glucose 
concentrations. 
 
                    
     
  
     (4.1)  
 
                 (4.2)  
 
           (4.3)  
 
The terms in Equation 4.1 are: p1 the glucose effectiveness; Gb the basal, or 
steady-state plasma glucose; Si the insulin effectiveness; f the fraction of meal 
carbohydrates that are available for absorption from the gut; kabs the rate at which 
carbohydrates are absorbed into the blood stream from the gut and VG the volume of 
plasma glucose distribution.  The terms in Equation4.2 are:  p2 the fractional rate of 
remote insulin clearance and Ib the basal plasma insulin concentration.  Lastly, the terms 
in Equation 4.3 are u the rate of insulin infusion or absorption into the plasma from an 
exogenous input and ke the clearance rate of insulin from the plasma. 
Subcutaneous Insulin Injection Model  
Numerous models have been proposed to describe the concentration of plasma 
insulin following subcutaneous injections.  One of the earliest models, proposed by 
Berger and Rodbard [6], is shown below in Equation 4.4.   
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       (4.4)  
 
Originally proposed to deal with early insulins such as NPH, lente and ultralente 
this model includes two insulin specific parameters s, an empirically determined scalar  
and T50 the time needed for 50% of the injected insulin to be absorbed into the plasma, as 
well as two generic parameters ke, which as before is the rate of insulin clearance from 
the plasma and Vi the distribution volume of insulin within the plasma.  While compact, 
the model is cumbersome in that it has a highly nonlinear insulin input term.  Further, 
recent work to extend this model to modern insulins, such as insulin aspart, is somewhat 
suspect, predicting an insulin distribution volume of 135L [7].  
For this reason, we have chosen to model the injection of rapid-acting insulin as 
an impulse and the injection of long-acting insulin as a step-function as shown below in 
Equation 4.5 and Equation 4.6.   
 
        
  
  
      (4.5)  
 
 
       
  
    
       
      
  
(4.6)  
 
The terms in Equation 4.5 are the size of the insulin dose Id and the distribution 
volume of insulin in the plasma Vi.  Equation 4.6 contains an additional term ta which is 
the length of time that a dose of long-acting insulin remains active.  For an ideal peakless 
once-per-day insulin, this would be 24 hours.  Equation 4.5 and Equation 4.6 are used to 
model the input u to Equation 4.3. 
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Meal Model  
Using data from 41 subjects, Dalla Man et al. [8] developed and validated a model 
of the gastric system which is described below in Equations 4.7 - 4.12. 
 
              (4.7)  
 
                 (4.8)  
 
                       (4.9)  
 
Terms in Equation 4.7 are: q1 the mass of carbohydrate in stomach compartment 
one, u the meal input and kemp the rate constant for gastric emptying.  Terms in Equation 
4.8 are: q2 the mass of carbohydrate in stomach compartment two and kabs the rate 
constant for carbohydrate absorption from the gut.  Finally, Equation 4.9 describes the 
mass of carbohydrates in the gut which is given by Ggut.   
Meals are modeled as the impulse response to Equation 4.7 – 4.9.  The impulse 
response for this coupled system is given in Equation 4.10 for a meal of containing a 
mass of carbohydrates D. 
 
          
                      (4.10)  
 
   
    
 
           
  (4.11)  
 
   
    
 
           
 (4.12)  
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Taken as a whole, Equations 4.1 – 4.3 and Equations 4.5 – 4.9 form the Extended 
Bergman Minimal Model (EBMM). 
CLINICAL INSULIN THERAPY PARAMETERS 
We concern ourselves now with the derivation of the insulin sensitivity factor, 
insulin-to-carbohydrate ratio and basal dose using the EBMM.   
Insulin Sensitivity Factor 
In the absence of any meals and assuming a steady-state we set the left-hand of 
both Equation 4.1 and Equation 4.2 to zero and find: 
 
 
   
    
      
  (4.13)  
 
          (4.14)  
 
Given that the EBMM treats insulin as deviations from a baseline concentration, 
Equation 4.13 allows us to calculate the effect of additional rapid-acting insulin on 
glycemia.  If we approximate the appearance of rapid-acting insulin following an 
injection of size Id as a step increase in the plasma insulin with some time length ta in an 
insulin distribution volume VI then: 
 
      
  
      
   (4.15)  
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Finally, we can calculate the ISF by using Equation 4.13 and noting that: 
 
          
    
      
      
  
    
  (4.16)  
 
    
    
        
  (4.17)  
 
     
  
  
  (4.18)  
 
where we have defined the Banting Number, a dimensionless plasma insulin 
concentration, as Ba in honor of Frederick Banting, that accounts for the kinetics of both 
glucose and insulin disposition in Equation 4.17.   
Insulin-to-Carbohydrate Ratio 
Next, we note that per Equation 4.1, preventing post-prandial hyperglycemia can 
be accomplished if: 
 
        
     
  
      (4.19)  
 
Assuming similar kinetics for the appearance of food in the gut and insulin in the 
plasma following a meal and insulin injection, we find that the I2C is given by: 
 
 
     
 
  
 
    
       
    (4.20)  
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Basal Insulin Dose 
Finally, to calculate the basal dose we make reference to Equation 4.15 and note 
that the basal insulin dose is given by: 
 
              (4.21)  
 
Equation 4.21 would be most appropriate for initiating new insulin therapy, for 
modifying an existing insulin regimen it is sufficient to use Equations 4.16 – 4.18 
ACCURACY, LIMITATIONS AND ASSUMPTIONS 
Dynamic Simplification 
Looking at Equations 4.13 and 4.19 we have exact relationships algebraic 
relationships relating the various states of our model to one another.  However, in 
developing the therapy calculators of Equation  4.18, Equation 4.20 and Equation 4.21—
which constitute a kind of static input/output model—we have made numerous 
simplifying assumptions to the dynamic EBMM.  
To assess the effect of this dynamic simplification we have constructed three test 
simulations which are shown in Figures 1 – 3.  Each test simulation was performed using 
the same parameter vector—shown in Table 4-1—and Equations 4.1 – 4.9.  Numerical 
integration was performed using ode45 in MATLAB 2010b.  All simulations were 
initialized at steady-state—i.e., G=Gb and I=X=Ib. 
To assess the validity of the approximations used in deriving the insulin 
sensitivity factor given by Equation 4.18, the glucose response to an injection of 0.1 U, 
0.5 U, 1.0 U and 2.0 U was simulated over a course of 12 hours.  Referring to Table 4 -1 
we see that per Equation 4.18 we have calculated an ISF of 45 mg/dL-U for this patient.  
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Looking at Figure 4-1, we see that for insulin doses of 0.1 U and 0.5 U the observed ISF 
is approximately 50  mg/dL-U, for the administration of 1.0 U of insulin the apparent ISF 
is  38 mg/dL-U and that for the administration of 2.0 U of insulin the apparent ISF is 29 
mg/dL-U.  It is thus clear that for small insulin doses, up to perhaps 1.0 U or slightly 
more, the dynamic simplifications in Equation 4.18 hold.   
Further, in arriving at an ISF of 45 mg/dL-U we have used the definition of the 
insulin sensitivity factor, as the drop in blood glucose brought about by a single unit of 
rapid-acting insulin, in Equation 4.16.  Building on Equation 4.16 and Equation 4.17, we 
now define a dimensionless blood glucose correction factor Co: 
 
    
  
  
  
  
    
   (4.22)  
 
Plotting the above in Figure 4-3 it is clear that Co is a nonlinear function of the 
dimensionless insulin concentration Ba.  As a result, ISF must also be a nonlinear 
function of Ba.  Noting this relationship, and using the parameters in Table 4-1, the ISF 
for 2 U of insulin is calculated to be 28 mg/dL-U in excellent agreement with the 
simulated result. 
As such, we see that the dynamic simplifications made to arrive at Equation 4.18 
are in fact quite robust.  Using Equation 4.18, the ISF can either be approximated with a 
linear scaling factor for small doses of insulin or calculated using the full nonlinear 
relationship for larger doses of insulin. 
To evaluate post-prandial glucose control using the insulin-to-carbohydrate ratio 
from Equation 4.29, we looked at the effect of a 70 g-CHO meal with and without the 
concurrent administration of 1.5 U of rapid-acting insulin.  The resulting blood glucose 
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trace is shown in in Figure 4-2.  In the absence of any insulin, post-prandial 
hyperglycemia is severe, peaking at 245 mg/dL and remaining above 140 mg/dL for at 
least three hours.  By contrast, when 1.5 U of insulin is administered along with the meal, 
glucose never rises above 120 mg/dL and bottoms out around 80 mg/dL.  From Table 4 -
1, we see that the apparent I2C is 52 g-CHO/U implying that 1.35 U of insulin are needed 
to cover the meal.  The remaining 0.15 U should produce a blood-glucose drop of 7 
mg/dL using the linear ISF or 10 mg/dL per the full nonlinear ISF.  However, we see that 
post-prandial glucose is depressed by as much as 20 mg/dL.  Thus, our dynamic 
simplification has introduced some error into the estimation of I2C.  However, as the 
discrepancy is relatively small, at 10 mg/dL, we feel that this source of error is negligible. 
We also, we wish to point out the role of insulin timing in proper glucose control.  
Tacitly, we have assumed that insulin administration should occur alongside each meal.  
However, it is commonly accepted that administering insulin prior to a meal can actually 
improve post-prandial glucose control and lower the risk of hypoglycaemia.  Shown in 
Figure 4-4 is the effect of administering rapid-acting insulin 15 minutes prior to each of 
three meals.  While both concurrent and prior administration of insulin is able to prevent 
post-prandial hyperglycemia, prior administration keeps blood glucose in a tighter band, 
having no excursions above 120 mg/dL and no excursions below 80 mg/dL.  By 
comparison concurrent administration of insulin allows post-prandial glucose to rise as 
high as 140 mg/dL and induces the patient to spend a significant amount of time at or 
near 75 mg/dL, a threshold value for some definitions of hypoglycaemia.  While it may 
not always be convenient for patients to do so and while our model does not explicitly 
account for optimal administration time, the advantages of early insulin administration 
are clear. 
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Finally, the approximation error introduced in our determination of the basal 
insulin dose is considered to be negligible as a series of ideal long-acting insulin 
injections would produce a totally flat profile as given by Equation 4.21. 
Identifiability 
As mentioned in previous chapters, identifiability is an important but often 
difficult to assess property of any model. 
Having mapped the EBMM to clinically relevant MDI parameters, we now wish 
to determine two things.  First, given home-use conditions is this model identifiable and 
second, if so how does uncertainty in model parameters propagate through to the insulin 
therapy recommendations. 
Experimental Conditions  
To answer this question we must first simulate home-use conditions and then 
perform sensitivity analysis on the EBMM. 
For all simulations, the EBMM was initialized with representative parameters 
reported in the literature and found in Table 4-1.  As before, the equations were 
numerically integrated in MATLAB 2010b using ode 45.  A twenty-four hour period was 
then simulated wherein the virtual patient awoke at 7:00 am and then consumed a total of 
200 g of carbohydrates in meals of equal size at 8:00 am, 12:00 pm, and 8:00 pm.  The 
prandial insulin dose was calculated using a linear ISF from Equation 4.20 and 
administered concurrent with the meal.  The basal insulin requirement was calculated 
using Equation 4.21.  Simulated glucose measurements were recorded using the above 
procedure with a ten-minute sampling of blood glucose without noise.  The results of this 
experiment are shown in Figure 4-5. 
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Fisher Information Matrix 
The Fisher Information Matrix—defined in Equation 4.25—allows us to estimate 
the variance of a given model parameterization from the sensitivity vector defined in 
Equation 4.23. 
 
        
      
   
  (4.23)  
 
Using the simulated measurements described above as well as the central 
difference approximation  in Equation 4.24 the sensitivity coefficients were calculated 
and stored [9].  
 
         
      
               
        
    
 (4.24)  
 
All parameters in the EBMM were perturbed 1% from their nominal value to 
evaluate Equation 4.24.   
The sensitivity vectors were then used to calculate the Fisher Information Matrix, 
which is given by: 
 
             
            
  
   
 
(4.25)  
 
where R is the state covariance matrix.  As only a single state is under consideration R is 
the variance of the glucose measurements, which was assumed to be 100 (mg/dl)
2
. 
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The Cramer Rao Bound allows us to find a lower bound for the parameter 
variance from the Fisher Information Matrix: 
 
    
           (4.26)  
 
Finally, assuming that all parameters must be greater than zero gives us an 
approximate necessary condition for the model’s a posteriori parameter identifiability; 
namely pj > 1.96σj.  This ensures that the 95% confidence interval for pj does not contain 
zero.   
Results of the sensitivity analysis are presented in Table 4-1 and demonstrate that 
the model is identifiable under the given conditions.  For all parameters, the coefficient of 
variation as calculated by the FIM is less than 9% meaning that the value zero is at least 
11 standard deviations away from the nominal parameter estimate.   
To examine the identifiability of the EBMM over a larger parameter space, 150 
random parameter vectors were generated where each element in the vector was given by 
a uniformly distributed random number that was +/- 30% of the nominal parameters in 
Table 4-1.  The identifiability analysis described above was repeated and the results are 
presented in Figure 4-6.  As before, all parameters are identifiable. 
Given that the meal and insulin inputs were selected to cancel each out, the 
simulated experiment is nearly as uninformative as is possible.  This fact, coupled with 
the identifiability of the model over a large swath of parameterizations, allows us to move 
forward with good confidence that the EBMM and the parameters in Equation 4.18, 
Equation 4.20 and Equation 4.21 will be identifiable in most circumstances. 
 46 
Propagation of Errors  
Having demonstrated identifiability of the EBMM, we now turn to the question of 
uncertainty in our therapy recommendations.   Parametric uncertainty in the EBMM will 
propagate through Equation 4.18, Equation 4.20 and Equation 4.21 and may produce 
undesirable controller performance.  The variances of the I2C and basal dose as 
determined from Equation 4.20 and Equation 4.21 are given by the following equations: 
 
     
   
  
     
 
 
   
   
  
     
 
 
   
   
  
      
   
 
  
 
  
  
     
    
 
     
   
(4.27)  
 
         
           
    
          
     
          
    
   (4.28)  
 
Evaluating Equation 4.27 and Equation 4.28 for the parameters in Table 4-1,  the 
coefficient of variation for I2C is 10.4% and the coefficient of variation for Id,basal is 
6.3%.  The coefficient of variation for ISF was evaluated numerically using MAXIMA, a 
computer algebra program, and has a value of 9.0%. 
Uncertainty in ISF is due almost entirely to the uncertainty in Gb.  While the other 
parameters in Equation 4.16 and Equation 4.17 would be difficult to estimate in a home-
use setting, Gb could be estimated from a measurement of fasting blood glucose in the 
morning.  Doing so could reduce the coefficient of variation to 4.2% if the measurement 
was sufficiently precise. 
The uncertainty in I2C is dominated by the second and fourth terms in Equation 
4.27.  As with ISF, it is difficult if not impossible to observe kabs under home-use 
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conditions, however, estimating Gb directly from a fasting blood glucose measurement in 
the morning could reduce the coefficient of variation of I2C to as little as 3.3%. 
Uncertainty in Id,basal is dominated by the first term in Equation 4.28.  
Unfortunately, unlike with I2C, there does not appear to be an easy way to reduce this 
uncertainty with supplementary observations.  However, as the standard error is already 
small, this uncertainty is acceptable for our purposes.  
SUMMARY AND CONCLUSIONS 
In this chapter we have developed aconnection between the EBMM and the 
clinically significant insulin therapy parameters of ISF, I2C and  basal dose.  For a 
representative set of model parameters, these treatment parameters were found to be 45 
mg/dL-U, 52 g-CHO/U and 12.6 U respectively.  These estimates for ISF and basal dose 
are in excellent agreement with values commonly used to treat T1DM [10], [11].  By 
contrast, the calculated value for I2C is a factor of 2-5 times higher than might be seen in 
practice.  This is attributed to the limitations of our meal model as well as the value of the 
nominal parameters.   
Using the Fisher Information Matrix we have shown that the EBMM is 
identifiable under home-use/ambulatory conditions from a stream of continuous glucose 
measurements.  This result was robust across a large range of parameter values and is 
necessary to determine patient-specific insulin therapy parameters by fitting the EBMM 
to a patient-specific data set. 
Lastly, the effect of uncertainty in the model parameterization on the calculation 
of ISF, I2C and the basal dose was evaluated.  The coefficients of variation for ISF, I2C 
and basal dose were found to be: 9.0%, 10.4% and 6.3% respectively.  The coefficients of 
variation for ISF and I2C could be further reduced to 4.2% and 3.3% respectively given a 
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sufficiently precise measurement of the fasting plasma glucose.  Given the limitations of 
insulin pens, which are rated to deliver small doses with an accuracy of +/- 10% and can 
at best deliver insulin in increments of 0.5 U [12], and that individuals tend to 
overestimate carb intake by as much as 20% [13], the effect of parameter uncertainty on 
controller performance appears to be acceptable. 
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Figure 4-1: Effect of Rapid-Acting Insulin on Plasma Glucose Concentrations 
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Figure 4-2: Effect of Rapid-Acting Insulin on Post-Prandial Hyperglycemia 
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Figure 4-3: Dimensionless Insulin Therapy Curve 
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Figure 4-4: The Effect of Insulin Timing on Post-Prandial Glycemia 
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Parameter Nominal 
Value 
     
p1 (min
-1
) 1.57 x 10
-2
 1.0 x 10
-3 
Gb (mg/dl) 100 7.9 
p2 (min
-1
) 1.23 x 10
-2
 4.3 x 10
-4
 
Si (L/min-U) 5.0 x 10
-1
 1.1 x 10
-2
 
ke (min
-1
) 1.82 x 10
-2
 5.2 x 10
-4
 
kabs (min
-1
) 1.20 x 10
-2
 3.8 x 10
-4
 
kemp (min
-1
) 1.80 x 10
-1
 1.5 x 10
-2
 
Vi (L) 12 3.0 x 10
-1
 
     
  
 (mg/dL-min-gCHO) 8.00 x 10
-2
 2.0 x 10
-3
 
Ib (U/L) 4 x 10
-2
 2.0 x 10
-3
 
ISF (mg/dL-U) 45 4.07 
I2C (g-CHO/U) 52 5.4 
Id,basal (U) 12.6 0.79 
 
Table 4-1: Nominal Parameter Values and Their Uncertainties 
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Figure 4-5: Identifiability of the Bergman Minimal Model 
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Figure 4-6: Identifiability of the EBMM across a range of parameters 
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Chapter 5: Parameter Identification – Personalizing Insulin Therapy 
Having developed a way to calculate clinical insulin therapy parameters, from the 
Extended Bergman Minimal Model, we now turn to the task of personalization through 
parameter estimation.  
Having been in use for over 30 years, the Bergman Minimal Model has been the 
subject of numerous parameter estimation studies.  Many focus on the model’s original 
purpose, which was to provide an estimate of insulin sensitivity from a controlled clinical 
experiment [1], [2].  Collecting data from either an intravenous glucose tolerance test 
(IVGTT), many researchers have had the advantage of measuring both glucose and 
insulin concentrations over the course of their experiment [3], [4], [5].  However, as we 
seek to develop personalized insulin therapy that may be adapted under home-use 
conditions, we must consider the case where insulin measurements are unavailable. 
METHODS 
To assess whether parameter identification can take place under home-use 
conditions we propose two simple experimental scenarios.  Test data is generated by 
creating two cohorts of patients based on the Extended Bergman Minimal Model and the 
more complicated Hovorka model.  In addition, two 24-hour segments of real CGM data 
with accompanying meal and insulin logs are also used.  Parameter estimation is then 
performed by fitting the Extended Bergman Minimal Model to the simulated or real data. 
By attempting to fit the Extended Bergman Minimal Model to measurements 
generated by the Hovorka model, as well as real CGM measurements, we can assess 
whether the insulin therapy calculators derived in Chapter 4 are robust enough to work in 
a real clinical setting. 
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The Hovorka Model 
The Hovorka Model of glucose-insulin dynamics is an eight compartment model, 
which encompasses three subsystems and includes three auxiliary equations.  Originally 
developed using labeled IVGTT data, the model has since been used to implement 
nonlinear model predictive control in clinical trials of closed-loop insulin therapy [6], [7].  
It is a compromise between the parsimony of the Bergman Minimal Model and the 
unwieldiness of larger more physiologically based models such as that of Sorensen [8]. 
Glucose Subsystem 
The glucose subsystem is composed of two compartments, described by the 
differential equations in Equation 5.1 and Equation 5.2, as well as the three auxiliary 
equations show in Equations 5.3 – 5.5. 
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Equation 5.1 describes the total mass of glucose found in the accessible 
compartment—i.e., the blood and interstitium.  The primary state variables include Q1 
and Q2 which are the masses of glucose in the accessible and inaccessible compartments.  
Parameters include: the distribution volume of glucose VG, the transfer coefficient 
between the glucose compartments k12 and the rate of endogenous glucose production at 
zero insulin concentration EGPo.   
The auxiliary terms are: the total insulin-independent rate of glucose consumption 
   
   given by Equation 5.3, the rate of renal glucose clearance Fr given by Equation 5.4 
and the rate of glucose absorption following a meal of size DG given by Equation 5.5.  
Equation 5.5 is the equivalent the impulse response of a two-compartment model with 
identical transfer rates        .  The final term in Equation 5.5 is AG the bioavailability 
of carbohydrates in the meal. 
Insulin Subsystem 
The absorption and elimination of insulin following subcutaneous administration 
are governed by Equations 5.6 – 5.8.   
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Equation 5.6 and Equation 5.7 model the transfer of insulin between two 
subcutaneous insulin compartments, S1 and S2, essentially acting as series low-pass filters 
between the insulin infusion rate u and the appearance of insulin in the plasma.  As in the 
meal model of Equation 5.5, the transfer rates between the compartments, given by 
        , are identical. 
Having passed through the subcutaneous compartments, the behavior of insulin in 
the plasma, state variable I, is governed by Equation 5.8.  Parameters in Equation 5.8 
include the distribution volume of insulin in the plasma VI and the rate of insulin 
clearance ke. 
While the work of Hovorka et al. [6] is primarily concerned with continuous 
subcutaneous insulin infusion—i.e., insulin pumping—we use this subsystem in 
conjunction with Equation 4.5 and Equation 4.6 when modeling subcutaneous insulin 
injections. 
Insulin Action Subsystem 
Finally, the pharmacodynamic action of insulin is governed by the three 
compartments of Equations 5.9 – 5.11.   
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State variables are x1, x2 and x3, which model the effect of insulin on glucose 
clearance in compartments Q1 and Q2 as well as endogenous glucose production.  A total 
of six activation and deactivation constants are given by kai, i = 1, 2, 3, and kbi, i = 1, 2, 3. 
Generating Test Data 
Two cohorts of virtual patients were generated from the models of Bergman and 
Hovorka.  To generate a patient, the nominal parameter vector from the model was taken 
and each entry was multiplied by a random number, uniformly drawn from between 0.7 
and 1.3.  This was repeated 150 times for the nominal parameters of the Bergman model 
and 30 times for the Hovorka model.  This method is equivalent to saying that for a given 
patient, each parameter is a random vector whose elements are uniformly distributed 
within +/- 30% of their expected or nominal value.  The nominal parameter values for the 
Bergman and Hovorka models are contained in Table 5-1 and Table 5-2. 
To give an example as to how realistic these virtual patients are, the ISF, I2C and 
ideal basal dose for both Bergman and Hovorka patients are presented in Figures 5-1 – 5-
3.  For the Bergman model, these were calculated directly from the model parameters.  
For the Hovorka model, these were determined by numerical simulation.   
To numerically calculate ISF, I2C and the ideal basal dose, each Hovorka patient 
was first given a 10 U dose of once daily long-acting insulin in the absence of any other 
insulin or meal inputs.  The basal dose was titrated in increments of 0.25 U until the 
patient reached a stable blood glucose concentration of between 90 mg/dL and 110 
mg/dL.  Having achieved fasting euglycemia, the ISF was determined by measuring the 
maximum drop caused by the administration of 1 U of rapid-acting insulin.  The I2C was 
then calculated by challenging the patient with a 50 g-CHO meal and 5 U of co-
administered rapid-acting insulin.  The insulin dose was titrated in increments of 0.25 U 
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until post-prandial glycemia was kept between a maximum of 160 mg/dL and a minimum 
of 80 mg/dL. 
In addition to simulated data, two 24-hour episodes of human CGM 
measurements from a single individual with T1DM were also used for model 
identification.  These CGM measurements were collected as part of a study conducted by 
Abbott Diabetes Care to evaluate the FreeStyle Navigator under home-use conditions.  
The two blood glucose traces, as well as the accompanying meal and insulin logs are 
presented below Figures 5-4 – 5-5 and Tables 5-3 and 5-4. 
Experimental Design 
Two experimental scenarios were considered for both the Bergman and Hovorka 
cohorts.   
In Scenario 1, each subject was injected with an ideal dose of long-acting insulin 
at t=0 and was subsequently provided with 50 g-CHO and 1 U of rapid-acting insulin at 
t=120 minutes.  Blood glucose measurements were recorded for a total of 720 minutes.  
In Scenario 2, each subject was injected with an ideal dose of long-acting insulin 
at t=0 and was subsequently provided with 50 g-CHO and 2 U of rapid-acting insulin at 
t=120 minutes, 70 g-CHO and 3 U of rapid-acting insulin at t=420 minutes as well as 30 
g-CHO and 1 U of rapid-acting insulin at t=660 minutes.  Blood glucose measurements 
were recorded over a total of 1440 minutes. 
To examine the significance of measurement frequency, sampling times of 1-
minute and 10-minutes were considered for both Scenario 1 and Scenario 2.   
To examine the significance of measurement noise, a noisy sample was created by 
adding Gaussian noise of mean zero and standard deviation 10 mg/dL to the 10-minute 
sampling in Scenario 2. 
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Finally, three different meal/insulin log errors were considered using noise-free 
data from Scenario 2 with a 10-minute sampling frequency.  For Error 1, the time-stamp 
on the first meal and insulin inputs was falsely recorded as t=90 minutes.  For Error 2, the 
recorded insulin amount was set to 0 for the second meal to simulate a log omission.  
Finally, for Error 3, the last meal is falsely recorded as having been 45 g-CHO to 
simulate incorrect estimation. 
Optimization  
As mentioned before, we wish to fit the parameters of the EBMM to our data so 
that we can estimate the ISF, I2C and ideal basal insulin dose of our patients. 
Typically, parameter estimation consists of minimizing the sum of squared errors, 
as in Equation 3.5, or another suitable objective function, between a set of reference data 
and a parameterized model.  While this approach works well for a wide variety of 
problems, parameter estimation in dynamic systems, such as the Bergman Minimal 
Model, is generally ill-conditioned and numerically unstable [9].  Because of this 
numerical instability and the computational cost associated with numerical integration, 
parameter estimation can be difficult.  As evidence, the standard approach of minimizing 
the sum of squared errors of the blood glucose measurements, produced no acceptable 
results when fitting the Bergman Minimal Model to data simulated using the Hovorka 
model or to the real CGM measurements shown in Figure 5-4 and Figure 5-5.   
To remedy this problem, a technique known as principal differential analysis 
(PDA) was utilized.  The procedure is described in Chapter 3, but briefly, splines were fit 
to our simulated data and used to calculate the derivative of the data at each time point tm.  
Then Equation 4.1 was used to calculate the derivative of the Bergman Minimal Model at 
the same time points.  To do this, the measured glucose was substituted in for G and the 
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meal and insulin logs were used to calculate X and Ggut.  The error between the derivative 
of the measurements and the derivative calculated by the model was minimized in 
MATLAB 2010b using lsqnonlin.  The optimization routine was initialized using the 
parameter values in Table 5-1 and the routine was provided with a lower bound of zero 
for each parameter and an upper bound of 1.8 times the nominal value. 
RESULTS AND DISCUSSION 
Below we summarize and discuss the results for parameter estimation using both 
simulated and real CGM data. 
Parameter Estimation in the Bergman Cohort 
Performing parameter estimation of the EBMM by using measurements simulated 
with the same model serves as a litmus test for the feasibility of our approach.  If 
parameter estimation was unsuccessful in the absence of any model mismatch, it could 
hardly be expected to succeed when looking at either a different model structure or actual 
human data. 
Fortunately, estimation of the parameters was completed successfully and a 
representative fit can be seen in Figure 5-6.  Looking at Table 5-5 we see that for each of 
the two scenarios and two sampling frequencies that, in the absence of noise, estimates of 
the ISF are fairly unbiased and have a standard deviation of around 10%.  The same is 
true for I2C with the exception of the 10-minute sampling of Scenario 2 with an average 
underestimation of 6.4%.  Similarly, we see that the ideal basal dose is estimated with 
nearly zero bias and a standard deviation of around 6%, except in the 10-minute sampling 
of Scenario 2 where a small overestimation of 2.4% was observed.  These biases in the 
10-minute sampling of Scenario 2 are assumed to be idiosyncratic, owing to numerical 
instability and not a fundamental result of the experimental protocol.   
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Recalling the identifiability results of Chapter 4, located in Table 4-1, these 
results are in line with the standard deviations estimated by the Fisher Information 
Matrix, which were 9.0% for the ISF, 10.4% for the I2C and 6.3% for the ideal basal 
dose.  
For the noisy measurement stream, our estimates suffered as expected.  The ISF 
and I2C showed an average underestimation of 4.3% and 15% respectively, while the 
ideal basal dose was overestimated by 7.2%.  The spread of estimate error also increased 
with the ISF, I2C and ideal basal dose having standard deviations of 15.0%, 17.8% and 
11.2% respectively. 
Finally, to provide a summary statistic for the goodness of fit, the mean amplitude 
of relative deviation was calculated for each fit.  The average MARD is reported in Table 
5-5 and for each noise-free measurement set was less than 1% increasing to 5.5% for the 
noisy measurement set. 
Considering estimation given errors in the meal/insulin log, we see that while 
estimates did worsen in general the effect of noisy CGM measurements was more 
significant than the errors that were considered.  A summary of these results can be found 
in Table 5-6.  
Parameter Estimation in the Hovorka Cohort 
Parameter estimation in the Hovorka Cohort was as expected more difficult.  One 
of the best fits is shown in Figure 5-7 and while certainly adequate, with an MARD of 
around 9%, in general the EBMM struggled to capture the full dynamic range of the 
Hovorka Cohort. 
However, despite this, both ISF and I2C were estimated successfully.  On 
average, estimates of the ISF have only a small negative bias and again have a standard 
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deviation of around 6% for all noise-free measurements sets.  Estimates of I2C suffer 
somewhat having a small negative bias of around 5% and a standard deviation of around 
10% as was the case with the Bergman Cohort.  However, estimates of the ideal basal 
dose are extremely poor, being consistently overestimated by a factor of 1.5.  The 
consistency of this overestimation is due to the one or more of the constraints in the 
optimization routine being active. 
The addition of noise has a smaller effect on parameter estimation in the Hovorka 
Cohort than in the Bergman Cohort.  The reason for this is unknown, but it is speculated 
that because the dynamic correspondence between the models was poor, as evidenced by 
an average MARD of between 20% and 28% for all scenarios, the addition of 10% 
Gaussian noise was not as impactful. 
As with the Bergman Cohort, time stamp errors and event magnitude errors had a 
minor impact on parameter estimation.  However, the omissions of log data caused 
significant underestimation of both the ISF and I2C.   
Data for overall estimation and estimation in the presence of log errors is 
presented in Table 5-7 and Table 5-8. 
Parameter Estimation from Real CGM Data 
The ability of the Bergman Minimal Model to fit real CGM data is shown in 
Figure 5-8.  The model errors are confined to within +/- 50 mg/dL and are nearly zero 
mean.  In addition, ISF, I2C and ideal basal dose were estimated as 18.28 mg/dL-U, 2.74 
g-CHO/U and 40 U.   
While unlike in the case of a synthetic patient, we cannot determine this 
individual’s true ISF as we can with virtual patients, we can estimate it using the so-
called Rule of 1800, which states that a person’s insulin sensitivity factor is 
 68 
approximately equal to 1800 divided by their total daily dose of insulin.  The relevant 
meal/insulin log for this fit is contained in Table 5-3 and indicates that on the day in 
question this person’s total daily dose was 95 U, including both rapid-acting and long-
acting insulin, implying an ISF of 18.95 mg/dL-U.  Further, we can see from inspecting 
Table 5-3 that this person was using between 3.33 U and 3.75 U of insulin for each 
carbohydrate they consumed.  Lastly, the person uses a total of 50 U of long-acting 
insulin split between the morning and early evening. 
This result allows for two possible interpretations.  First, it is possible that this 
person is already receiving their ideal therapy and that discrepancy between the estimated 
and observed insulin-to-carbohydrate ratio and basal dose is a result of parameter 
underestimation.  Alternatively, one can interpret this to say that our insulin therapy 
framework is recommending that this individual should decrease their basal dose by 10 U 
and increase their meal-time insulin by about 30%. 
Regardless, successful parameter estimation given real CGM data was no mean 
feat.  Unlike parameter estimation in the Bergman and Hovorka cohorts, which was 
performed using a single initial parameter guess, dozens of initial parameter guesses were 
considered before the result shown in Figure 5-8 was reached.  Further, parameter 
estimation given the second segment of CGM data was not successful. 
SUMMARY AND CONCLUSIONS 
Parameter estimation of the Bergman Minimal Model under home-use conditions 
was performed for two cohorts of virtual patients, one generated from the Extended 
Bergman Minimal Model itself and the over generated using the Hovorka model.  In 
addition, parameter estimation was also performed using two segments of real CGM data. 
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For the cohort of patients simulated using the Bergman Minimal Model, good 
estimates for the ISF, I2C and basal insulin dose were found in the absence of noise or 
meal/insulin log errors.  The addition of noise or log errors decreased the quality of 
parameter estimates and increased their distribution, but the results were still acceptable. 
Similar results were obtained for the Hovorka Cohort, with the exception that the 
basal dose was very poorly estimated and that omission errors in the log caused a 
significant degradation in parameter estimation.  Promisingly, while the presence of 
measurement noise caused a slight underestimation in the ISF and I2C, their variance was 
not significantly inflated as with the Bergman Cohort. 
Finally, successful parameter estimation was possible for only one of the two 
segments of real CGM data and only then after a significant effort was expended.  
However, estimates of the ISF, I2C and basal insulin dose calculated from equations of 
Chapter 4 are in good agreement with those inferred from the individual’s recorded log.  
Given these results, it appears that using CGM data collected under home-use 
conditions it is possible to directly identify person-specific values for the insulin 
sensitivity factor, insulin-to-carbohydrate ratio and basal insulin dose with both accuracy 
and precision.   
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Parameter Nominal Value 
p1 (min
-1
) 1.57 x 10
-2
 
Gb (mg/dl) 100 
p2 (min
-1
) 1.23 x 10
-2
 
Si (L/min-U) 5.0 x 10
-1
 
ke (min
-1
) 1.82 x 10
-2
 
kabs (min
-1
) 1.20 x 10
-2
 
kemp (min
-1
) 1.80 x 10
-1
 
Vi (L) 12 
Vg (L) 12 
Ib (U/L) 4 x 10
-2
 
 
Table 5-1: Nominal Parameters for the Bergman Model 
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Parameter Nominal Value 
k12 (min
-1
) 6.6 x 10
-2
 
ka1 (min
-1
) 6.0 x 10
-3
 
ka2 (min
-1
) 6.0 x 10
-2
 
ka3 (min
-1
) 3.0 x 10
-2
 
ke (min
-1
) 1.38 x 10
-1
 
Vi (L/kg) 1.2 x 10
-1
 
Vg (L/kg) 1.6 x 10
-1
 
Ag  8.0 x 10
-1
 
Tmax,g (min) 40 
Tmax,i (min) 55 
SIT (mU/L-min) 5.12 x 10
-3
 
SID (mU/L-min) 8.2 x 10
-4
 
SIE (mU/L-min) 5.2 x 10
-2
 
EGPo (mmol/kg-min) 1.61 x 10
-2
 
F01 (mmol/kg-min) 9.7 x 10
-3
 
Weight (kg) 78 
Median Basal Insulin Dose (U) 8.5 
Median ISF (mg/dL-U) 46 
Median I2C (g-CHO/U) 25 
Table 5-2: Nominal Parameters for the Hovorka Model 
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Figure 5-1: Insulin Sensitivity Factor of Synthetic Patients 
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Figure 5-2: Insulin-to-Carbohydrate Ratios of Synthetic Patients 
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Figure 5-3: Basal Insulin Requirements of Synthetic Patients 
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Figure 5-4: Real CGM Measurements: Segment One 
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Figure 5-5: Real CGM Measurements: Segment Two 
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Event Type Event Size Event Time (minutes) 
Insulin: Long-acting 25 U 41 
Insulin: Rapid-acting 12 U 41 
Meal 45 g-CHO 42 
Insulin: Rapid-acting 12 U 310 
Meal 45 g-CHO 310 
Insulin: Rapid-acting 12 U 632 
Meal 45 g-CHO 632 
Insulin: Rapid-acting 9 U 890 
Meal 30 g-CHO 891 
Insulin: Long-acting 25 U 891 
Table 5-3: Meal and Insulin Log for a Person with Diabetes 
 
  
 78 
Event Type Event Size Event Time 
Insulin: Long-acting 25 U 20 
Insulin: Rapid-acting 25 U 20 
Insulin: Rapid-acting 14 U 20 
Meal 45 g-CHO 20 
Insulin: Rapid-acting 12 U 309 
Meal 45 g-CHO 310 
Insulin: Rapid-acting 20 U 331 
Meal 75 g-CHO 333 
Meal 45 g-CHO 620 
Insulin: Long-acting 12 U 662 
Meal 30 g-CHO 846 
Insulin: Rapid-acting 10 U 846 
Insulin: Long-acting 25 U 847 
Table 5-4: Meal and Insulin Log for a Person with Diabetes 
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Figure 5-6: Model fit in the Bergman Cohort 
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 Scenario 1 
(1-minute) 
 
Scenario 1 
(10-minute) 
 
Scenario 2 
(1-minute) 
 
Scenario 2 
(10-minute) 
 
Scenario 2 
(Noisy) 
 
ΔISF (%) 0.8 ± 9.4 1.7 ± 12.0 0.3 ± 10.4 0.6 ± 11.0 -4.3 ± 15.0 
ΔI2C (%) 1.6 ± 9.9 0.2 ± 9.7 0.7 ± 9.9 -6.4 ± 9.7 -15.0 ± 17.8 
ΔBasal (%) 0.5 ± 6.0 -0.03 ± 5.9 0.43 ± 4.8 2.6 ± 6.0 7.2 ± 11.2 
MARD (%) 0.2 0.8 0.47 0.9 5.5 
Table 5-5: Parameter Estimation in the Bergman Cohort 
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 Log Error 1 
(Time Stamp) 
Log Error 2 
(Log Omission) 
Log Error 3 
(Event Magnitude) 
ΔISF (%) -1.9 ± 11.8 -0.08 ± 12.2 -2.4 ± 1.2 
ΔI2C (%) -11.4 ± 14.1 -0.2 ± 15.9 -6.7 ± 14.6 
ΔBasal (%) 2.6 ± 8.7 0.8 ± 6.9 2.1 ± 6.3 
MARD (%) 2.5 1.1 1.3 
Table 5-6: Parameter Estimation in the Bergman Cohort with Log Errors 
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Figure 5-7: Model fit in the Hovorka Cohort 
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 Scenario 1 
(1-minute) 
Scenario 1 
(10-minute) 
Scenario 2 
(1-minute) 
Scenario 2 
(10-minute) 
Scenario 2 
(Noisy) 
ΔISF (%) -1.0 ± 6.0 -0.8 ± 6.1 -3.5 ± 6.6 0.2 ± 6.0 -4.0 ± 6.8 
ΔI2C (%) -5.0 ± 10.0 -4.7 ± 10.1 -7.5 ± 9.3 -4.9 ± 9.3 -6.9 ± 9.4 
ΔBasal (%) 154.3 ± 14.8 154.3 ± 14.8 154.0 ± 15.1 151.0 ± 18.2 154.0 ± 14.8 
MARD (%) 20.6 20.5 27.0 28.5 28.6 
Table 5-7: Parameter Estimation in the Hovorka Cohort 
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 Log Error 1 
(Time Stamp) 
Log Error 2 
(Log Omission) 
Log Error 3 
(Event Magnitude) 
ΔISF (%) -0.6 ± 6.9 -12.0 ± 6.0 0.07 ± 6.0 
ΔI2C (%) -4.7 ± 9.4 -15.6 ± 8.2 -5.0 ± 9.3 
ΔBasal (%) 154.3 ± 14.8 151.0 ± 18.2 151.0 ± 18.3 
MARD (%) 29.1 32.9 28.6 
Table 5-8: Parameter Estimation in the Hovorka Cohort with Log Errors 
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Figure 5-8:  Fit of the Bergman Minimal Model to Real CGM Data 
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 Estimated from Bergman 
Minimal Model 
Inferred from 
Meal/Insulin Log 
ISF (mg/dL-U) 18.28 18.94 
I2C (g-CHO/U) 2.74 3.54 
Basal Dose (U) 40 50 
Table 5-9: Estimated and Inferred Treatment Parameters for Real Data 
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Chapter 6: The Physiology of Continuous Glucose Monitoring  
The development of continuous glucose monitoring (CGM) has created a number 
of opportunities for improving the treatment and management of T1DM.  For example, 
prior to the development of CGM, the implementation of ambulatory closed-loop insulin 
control was infeasible.  Using CGM, numerous researchers are pursuing closed-loop 
insulin control [1], [2], some even envisioning a future where CGM-based meal detection 
makes the entire process of insulin delivery self-managing [3].  In addition, the ability to 
provide immediate feedback on how life choices affect glycemia is widely recognized as 
beneficial and has been shown to lower A1C absent any other intervention [4], [5], [6].  
However, several factors currently limit the utility of CGM.  Among these 
limitations are the accuracy and precision of measurements, issues with calibration, cost, 
limitations on FDA approved uses, reimbursement and education [1], [6], [7].  In 
addition, there are many anecdotal reports indicating that sensors tend to underestimate 
blood glucose at night or when a user lays heavily on the device.1 
Numerous studies have evaluated the accuracy and performance of CGM devices; 
however, none of these authors have approached CGM device performance from a 
physiological basis.  In this chapter, we propose a physiological model of the CGM 
environment.  This model is used to analyze how different calibration schemes can affect 
the accuracy and precision of measurements derived from CGM.  In addition, by 
considering the underlying physiology, we are able to demonstrate the potential causes 
for some of the technology’s performance limitations.   
                                                   
1 In fairness, given that complaints tend to arise from night-time alarms resulting from false lows it is 
entirely possible that these anecdotes are the result of an easily remembered annoyance and not a failure of 
CGM technology. 
 89 
CONTINUOUS GLUCOSE MONITORING IN THE SKIN 
When discussing CGM, we are most concerned with the subcutaneous layer of the 
skin.  The subcutis or subcutaneous layer is between 10 – 15 mm in thickness and is 
located between 1.2 –  3.8 mm beneath the skin’s surface;  it is here that the probe of a 
CGM device is intended to analyze glucose content [8].  In the subcutis, capillary glucose 
is transported by convection and diffusion out of the capillaries and into the interstitial 
compartment—the extracellular environment in which the capillaries and other vessels 
are contained.  Small lymphatic vessels permeate the interstitial space, much like the 
capillaries, allowing excess fluid and protein seepage from the capillaries to be removed.  
Because CGM devices actually measure interstitial glucose and not blood glucose, their 
performance will depend on the dynamic interplay of glucose transport between the 
capillaries, the interstitial compartment and the lymphatics. 
MODELING INTERSTITIAL GLUCOSE DYNAMICS 
Previous authors, when they have described the physical environment of the CGM 
device, have consistently omitted any mention of the lymphatics. However, researchers 
who study drug and solute disposition in skin have identified the singular importance of 
the role played by the lymphatics [9].  
As such, we propose the following lumped model governing the disposition of 
glucose between the blood, interstitial compartment and lymphatics: 
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Terms in Equation 6.1 include: GB, GI and GL the concentrations of glucose in the 
blood, interstitium and lymphatics; VI  and VL the volumes of the interstitial and lymphatic 
compartments; Pcap and  Plym the permeabilities of the capillary and lymphatic vessels; Scap 
and Slym  the available surface area for transport across the capillary and lymphatic 
membranes; kI and kL the rate of glucose consumption in the interstitial and lymphatic 
compartments; and Q the rate of convective fluid flow from the capillaries into the 
interstitial compartment.   
IDENTIFYING SOURCES OF UNCERTAINTY IN CONTINUOUS GLUCOSE MONITORING 
A large body of work exists quantifying the accuracy and precision of CGM 
devices [10]–[13].  However, most work done on calibration is proprietary as it is of the 
greatest interest to manufacturers [14]–[16].  Further, while it is known that there is a lag 
or time delay between CGM measurements and the true blood glucose concentration, this 
particular problem has been primarily studied using empirical models in an attempt to 
quantify the lag and its effect on performance [17]–[19]. 
Below, we examine both one-point and two-point calibration schemes using the 
physiological model presented in Equations 6.1 and 6.2.  While CGM manufacturers all 
have proprietary calibration procedures that no doubt take into account factors such as 
drift, variance in manufacturing and commonly observed error patterns, it is hoped that 
this analysis will still prove informative. 
Calibration 
Because CGM devices measure the concentration of glucose in the interstitial 
compartment and not in the blood, a glucometer is needed to calibrate the device.  In 
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addition to an initial calibration, follow-on calibration is required at least every other day 
with some manufacturers recommending twice daily calibration.   
Ignoring the issue of sensor drift, we sought to explore whether one-point or two-
point initial calibration was superior.  To evaluate this we used Equation 6.1 and 
Equation 6.2 along with the EBMM discussed extensively in Chapter 4.  First, a blood 
glucose trace was simulated using the EBMM for two different sets of meal and insulin 
inputs.  Equations 6.1 and 6.2 were then numerically integrated in MATLAB 2010b with 
ode45 using the previously simulated blood glucose trace as an input to Equation 6.1.  
The specific parameters used in Equation 6.1 and 6.2 are shown in Table 6-1.  Figure 6-1 
shows a trace of blood glucose concentration and the uncalibrated interstitial glucose 
concentration for one of the two simulated cases. 
Calibration of the interstitial signal was then performed as follows.  For single-
point calibration a time-point was selected and the calibration factor (CF) was given by: 
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where Gb is the blood glucose concentration, GI is the interstitial glucose concentration 
and tcal is the time the calibration was performed.  The calibrated blood glucose value was 
calculated by multiplying each interstitial blood glucose value by CF. 
 For two-point calibration, a simple linear model was selected.  The parameters in 
the linear model were selected to satisfy the equation: 
 
                       6.4  
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Each pair of calibration measurements specifies a fully-determined linear system 
given Equation 6.4.  Solving this system for a and b, we then found the calibrated blood 
glucose value by substituting into Equation 6.4.   
Calibration was performed only when the rate of change of blood glucose 
concentration was close to zero.  In addition, two-point calibration was only performed at 
consecutive extrema that were separated by at least one hour.  Example calibrations are 
shown in Figures 6.3 – 6.5.   
To evaluate these calibrations, we used the mean absolute relative deviation 
(MARD), an industry standard used to evaluate CGM performance.  MARD is calculated 
by taking the difference between a set of calibrated measurements and reference 
measurements, dividing each difference by the corresponding reference measurement and 
then taking the mean of the absolute value of these relative deviations.  
Figure 6-3, which shows the results for three different single-point calibrations, is 
representative of the general performance of single-point calibration.  The calibrations 
took place at 25 minutes (a minima), 80 minutes (during a time of rapid rise in the blood 
glucose concentration) and at 125 minutes (a maxima).  The MARD for each of these 
three calibrations was found to be 8.4%, 7.0% and 11.4% respectively.   
Considering the extra effort involved, one would hope that a two-point calibration 
would produce better results.  In Figure 6-4, calibration measurements were taken at 50 
minutes and 150 minutes for the “Minima-Maxima” calibration and at 25 minutes and 
310 minutes for the “Minima-Minima” calibration.  In Figure 6-5, calibration 
measurements were taken at 45 minutes and 125 minutes for the “Minima-Maxima” 
calibration and at 45 minutes and 175 minutes for the “Minima-Minima” calibration.   
Examining Figures 6-4 and 6-5 we see that the extra effort does not always pay 
off.  Specifically, it is possible to choose calibration times such that the system of 
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equations formed by Equation 6.4 is nearly singular.  In this case, one can produce 
catastrophically bad calibrations as seen in the two “Minima-Maxima” calibrations.  The 
MARDs for these two calibrations are 106.5% and 78.6% respectively.   
To evaluate the issue of calibration more systematically, for each of the traces in 
Figure 6-4 and Figure 6-5, we performed all allowable calibrations as per the earlier 
defined rules and compared the results.  In total, 21 one-point and 18 two-point 
calibrations were performed. 
With respect to robustness, one-point calibrations are superior as the worst-case 
MARD was found to be 10.86% with the average MARD being 5.98%.  By contrast, 
naïve two-point calibration is capable of spectacular failures as shown in Figure 6-4 and 
Figure 6-5.  The worst-case MARD for two-point calibration was found to be 53.12% and 
the average MARD was found to be 21.35%.  However, as mentioned before poor two-
point calibration results from the creation of a nearly singular calibration system using 
Equation 6.4.  If one restricts calibrations to those where a large change in blood glucose 
has taken place, the problem of singularity can be avoided.   Considering only the two-
point calibrations where blood glucose changed by at least 60 mg/dL between calibration 
points, the worst-case MARD decreases to 6.55% and the average MARD is 5.19%.  In 
addition, MARD from two-point calibration is lower than the corresponding one-point 
calibration in all but two cases, with an average relative decrease of 4% and a median 
decrease of 3%. 
Capillary Bed Perfusion 
Assuming that manufacturers use one-point calibration in their meters, the above 
analysis helps to explain a MARD of around 6%.  However, studies have shown that for 
CGM devices MARD can range between 14% - 20% depending on the manufacturer 
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[10], [13].  While some of this discrepancy can be explained by the absence of additive 
noise in our model, as well as the presence of manufacturing variability between lots 
[20], [21], we propose that variations in perfusion of the capillary bed are also significant. 
In Equation 6.1 we modeled capillary perfusion as a constant Scap.  However, 
capillary perfusion is dependent on the perfusion of independent capillary vessels [22].  
On average, the capillary bed is approximately 40% perfused, meaning that blood is 
actively flowing through only 40% of all available vessels [9].  However, during periods 
of exertion this can increase to 100% and during periods of inactivity this value will 
certainly decrease below the average [23].  To model this variability we choose to look at 
both random changes in perfusion, which may result from sudden movement or exertion, 
as well as diurnal variability in perfusion, which would arise from natural shifts in 
activity level over the day. 
 
                        
  
    
     6.5  
 
                     6.6  
 
Equation 6.5 describes the case of diurnal variability and assumes that perfusion 
varies 25% about its mean in a sinusoidal fashion over a period of 24 hours.   
Equation 6.6 describes the case of random variations to capillary perfusion.  Here 
we only consider random increases to perfusion, modeling r as a uniformly distributed 
random number between 0 and 0.6. 
To explore how this variability in capillary bed perfusion affects CGM 
performance, a 24-hour blood glucose trace was simulated using the EBMM as before 
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with the parameter Scap in Equation 6.1 being modeled using Equation 6.5 or Equation 
6.6.  One-point calibration was performed 80 minutes into the simulation.  For simplicity, 
two-point calibration was not performed.  The results of these simulations are shown in 
Figures 6-6 – 6.8.  
Considering first the case of diurnal variations in perfusion, we see from Figure 6-
6 that this kind of variability can cause significant errors in CGM measurements.  For the 
case of constant perfusion also shown in Figure 6-6, the MARD is 3.5%.   By contrast, 
the MARD under the assumption of diurnal perfusion is 8.5%.  Interestingly, the error in 
the calibrated CGM signal is actually lower for the case of diurnal variability leading up 
to around 7:00 pm in the evening.  As a result, any follow-up glucometer readings are 
likely to lull the user into a sense of relative security.  If the user were then to make a 
treatment decision later in the evening without first consulting a glucometer, the 
overestimation of blood glucose caused by the diurnal change in capillary perfusion 
would cause overtreatment and could induce hypoglycemia. 
Turning our attention to Figure 6-7, we see that random diurnal variations in 
capillary perfusion could very easily be confused for additive measurement noise.  While 
the noise appears to be zero mean, there is still an accompanying decrease in CGM 
performance with MARD increasing to 6.7%.  An interesting feature that is also worth 
noting is the large decrease around 850 minutes.  This error looks very much like a 
“drop-out” or attenuation event, which is a specific kind of CGM system fault that is 
familiar to those in the industry, but has not been widely discussed in the literature [24]. 
Finally, turning to Figure 6-8 the composition of diurnal and random variations is 
shown.  While not qualitatively different from either of the preceding cases, CGM 
performance is further degraded with a MARD increasing to 10.4%.  This suggests that 
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the errors introduced by diurnal variations and those induced by random variations in 
capillary bed perfusion may propagate additively or can at least be modeled as such.2   
Externally Applied Pressure 
Mentioned briefly in the preceding section, drop-outs are transient decreases in 
CGM measurement that produce a marked underestimation of blood glucose similar to 
the one shown in Figure 6-7.  While not widely discussed in the literature, some drop-
outs have been attributed to the application of external pressure at the CGM measurement 
site [24]. 
Looking at Equations 6.1 and 6.2 it is not obvious how pressure would explain the 
occurrence of these events.  However, a deeper look at the physiology of the lymphatics 
provides some clue.  The primary lymphatics, which collect fluid from the interstitial 
compartment, are connected to the surrounding tissues by filaments [25].  As the volume 
of the interstitial compartment expands, these filaments pull on the lymphatics allowing 
fluid to enter [25].  In the presence of an applied pressure, the lymphatic vessels would be 
held shut preventing fluid collection.  To prevent local edema the body could respond by 
decreasing capillary perfusion, decreasing capillary permeability or by modulating local 
pressure fields which would reduce Q.   
To simulate the effect of applied external pressure, we use the same blood glucose 
trace as shown in Figure 6-2, and induce a drop in Q to 20% of its nominal value at 600 
minutes.  This simulation is shown in Figure 6-8.   
The effects of the applied pressure do not actually manifest themselves for over 
an hour despite a rapid decrease in the underlying blood glucose signal.  However, once 
                                                   
2 The root of the sum of the squared MARDs for the case of diurnal variations and the case of random 
variations to capillary bed perfusion is 10.81% which is close to the observed MARD for the composite 
case. 
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the blood glucose begins to rise rapidly at 680 minutes, the increased lag caused by the 
reduction in flow produces a drop-out of over 20 mg/dL.  Subsequently, lower rates of 
change and then a large period of decreasing blood glucose allows the measurement 
signal to catch up with the true signal decreasing the apparent magnitude of the drop-out.  
However, another rapid rise in blood glucose would likely produce the same sort of 
underestimation observed at 680 minutes.  While the delay between applied pressure and 
the observation of a drop-out does not agree with the observations of Baysal et al. [24], it 
is possible that there are multiple artifacts, each with a different cause, that have been 
lumped together as drop-outs or attenuation events. 
SUMMARY AND CONCLUSIONS 
We have shown that under some circumstances, two-point calibration of CGM 
devices is superior to one-point calibration by a relative 3% - 4%.  However, two-point 
calibration requires that the calibration measurements be taken at times when the rate of 
change in blood glucose is small and that the difference in blood glucose concentration 
between the first and second measurement be large.  If this second condition is not met, 
the calibration can fail catastrophically.  One-point calibration by contrast only requires 
that the rate of change in blood glucose concentration be small.  Therefore, we believe 
that one-point calibration should be the prevailing standard with optional two-point 
calibration occurring only when both conditions for adequate performance are satisfied. 
In addition, our simulations suggest that CGM performance is limited as much by 
the underlying physiology of the interstitial compartment as by the chosen calibration 
method.  Variations in capillary bed perfusion, arising from diurnal changes as well as 
random changes in activity level, increase MARD by 3.2% - 6.9%.  While there is no 
immediate remedy to the issue at hand, this result suggests future directions for 
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improving CGM performance.  For example, diurnal variations in capillary bed perfusion 
may very well depend on CGM insertion site.  If a location on the body can be found 
where capillary bed perfusion is stable over time, diurnal variations in CGM error can be 
minimized.  Further, minimizing the effect of random or unexpected changes in activity 
on CGM may be accomplished by combining activity data with CGM data.  The rise of 
motion tracking devices, including the Lark (Lark Technologies, Mountain View, CA), 
Fitbit (Fitbit Inc., San Francisco, CA) and software-enabled smartphones provides an 
additional stream of information that could be used to build a more robust calibration 
model. 
Finally, two potential mechanisms for the occurrence of drop-outs have been 
identified.  First, random variations in capillary bed perfusion, due to activity for 
example, can induce transient drops in CGM measurement output of as much as 80 
mg/dL.  One such event, extending for nearly an hour is visible in Figure 6-7.  This 
mechanism does not appear to have been previously reported and while no remedy is 
apparent, a diagnosis of the cause is still useful.  In addition, externally applied pressure 
can also induce drop-outs as shown in Figure 6-8.  While this mechanism has been 
anecdotally reported, understanding the physical mechanism that causes pressure-induced 
drop-outs should allow medical device manufacturers to design future CGM devices in 
such a way as to minimize or redistribute the transmission of an externally applied 
pressure gradient to the CGM microenvironment. 
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Figure 6-1: Schematic of the Sensing Environment of a CGM Device. 
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Model Parameter Value 
VI (L) 4.2 
VL(L) 9.4 
Pcap (cm/s) 1 x 10
-5 
Scap (cm
2
/g) 100 
Plym 10
-5
 
Slym (cm
2
/g) 100 
σf 2.0 x 10
-2
 
kI (min
-1
) 2.0 x 10
-3
 
kL (min
-1
) 2.0 x 10
-3
 
Q (mL/min) 70.0 
Table 6-1: Parameters for Lymph-Interstitial Model 
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Figure 6-2: Comparison of Blood and Interstitial Glucose Concentrations 
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Figure 6-3: The effect of Timing on Single-Point Calibration 
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Figure 6-4: Two-Point Calibration of a CGM Device 
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Figure 6-5: Failed Two-Point Calibration of a CGM Device 
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Figure 6-6: CGM Performance – Diurnal Variations in Capillary Perfusion 
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Figure 6-7: CGM Performance – Random Variations in Capillary Perfusion 
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Figure 6-8: CGM Performance – Random and Diurnal Variations in Capillary Perfusion 
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Figure 6-9: Pressure Induced drop-out in CGM Measurements
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Chapter 7: Conclusions 
The overall goal of this work was to use the methods of mathematical modeling as 
well as the recently developed continuous glucose monitors to develop a new way of 
estimating clinical insulin therapy parameters. 
To this end, the Bergman Minimal Model was used to derive control laws 
defining the insulin sensitivity factor, insulin-to-carbohydrate ratio and basal dose of 
insulin.  It was shown that, despite the simplifying assumptions used to derive them, 
these control laws performed well under simulation settings.  In addition, the predicted 
insulin sensitivity factor, insulin-to-carbohydrate ratio and basal dose were in excellent 
agreement with typical values seen in T1DM [1], [2].  Model identifiability was also 
verified using the Fisher Information Matrix and uncertainty in the clinical insulin 
therapy parameters was shown to be small. 
Having developed a control law, and verifying that its parameters could in 
principle be identified, we turned our attention to the personalization of our insulin 
therapy calculator via parameter estimation.  Two cohorts of synthetic persons with 
diabetes were generated using the Bergman Minimal Model and the more complicated 
Hovorka Model.  For both cohorts parameter estimation was performed for two different  
experimental settings and two different measurement frequencies assuming the 
availability of CGM measurements.  The first experiment was comprised of a single meal 
and insulin event followed by a period of continuous measurement.  This type of 
experiment could be performed immediately before a physician’s visit.  The second 
experiment mimicked a full day of continuous glucose measurement, involving three 
meals of different size, four total insulin injections and twenty-four hours of recorded 
measurements, but was also considered simple enough to be performed at home without 
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supervision.  The issue of measurement noise as well as errors in the recording of meal 
and insulin logs was also simulated. 
Overall, parameter estimation in both the Bergman and Hovorka cohorts was 
successful, although the estimation of basal insulin dose in the Hovorka cohort could not 
be accomplished.  As expected, measurement noise and log errors resulted in degraded 
parameter estimates.  However, the effect of noise on parameter estimation in the 
Hovorka cohort was smaller than in the Bergman cohort.  Given that the Hovorka cohort 
is viewed as a more realistic test setting, this was a favorable result.  In addition, it 
appears that parameter estimation is only strongly affected by major log errors such as the 
complete omission of an entry.  Errors in the recorded time of a meal or insulin event as 
well as smaller errors in the magnitude of the event did not produce large errors in 
parameter estimation. 
Finally, parameter estimation using real CGM measurements was successfully 
performed with one of two available measurement sets.  The estimated insulin sensitivity 
factor, insulin-to-carbohydrate ratio and basal insulin dose agreed well with those 
inferred from the individuals recording of meal and insulin intake. 
The last issue explored was the physiology of CGM measurement and how this 
physiology may provide a fundamental limit to CGM accuracy and precision.  To address 
this issue, a physiologically-based model of the subcutaneous skin was proposed.  This 
model included compartments to describe the dynamics of both interstitial and lymphatic 
glucose transport and was parameterized using representative values compiled from the 
literature.  Under stable capillary bed perfusion, it was shown that reasonable calibration 
schemes can yield blood glucose estimates from CGM that have an error of roughly +/- 
5%. 
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However, as it is known that capillary bed perfusion is variable [3] we sought to 
quantify how this variability might affect CGM accuracy and precision, considering both 
diurnal and random variations in capillary bed perfusion.  Diurnal variations were shown 
to increase the average error in CGM measurements by nearly a factor of three, whereas 
random variations more than doubled average error.  In character, diurnal variations 
tended to cause systematic estimation biases whereas random variations merely increased 
variance of parameter estimates.  As this was only a simulation study, it is difficult to 
assess whether the physiology of the subcutaneous tissues really holds so much sway 
over CGM accuracy and precision or whether in real CGM devices other sources of error, 
including manufacturing variability and device stability, may be more significant.  
Regardless, the novelty of this analysis should still be valuable if only in sparking 
discussion. 
SIGNIFICANCE FOR THE TREATMENT OF DIABETES 
As discussed in Chapter 1, as many as two-thirds of Americans with T1DM fail to 
achieve ADA targets for good glycemic control, leading to a host of economic and 
human health consequences.  Further, current insulin titration protocols often take a long-
time to produce good results and in many cases are unable to bring patients into control 
[4]–[7].   
Alternatives to traditional insulin titration protocols include techniques to 
augment insulin titration through structured visualization of patient data [8]–[10] as well 
as complete departures from insulin titration such as the artificial pancreas [11]–[13] and 
approaches that are somewhere between these extremes such as decision support systems 
[14].  Further, each of these approaches has its own set of advantages and shortcomings 
as compared to traditional insulin titration.   
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In the case of augmented insulin titration protocols, structured visualization 
techniques make interpreting patient data faster and easier.  In addition, because data is 
collected automatically with a continuous glucose monitor and because one is searching 
for qualitative patterns, self-reported blood glucose measurements as well as self-reported 
meal and insulin logs are less important.  Given the challenges of correctly estimating 
meal carbohydrates [15], [16], issues of patient adherence to insulin therapy [17] and the 
tendency of persons with diabetes to omit hyperglycemic and hypoglycemic blood 
glucose measurements [18], whether consciously or unconsciously these are non-trivial 
benefits. 
Despite this, augmented insulin titration protocols may still suffer from the main 
problem facing standard insulin titration protocols.  Namely, that good control will still 
elude as many as 62% of treated patients [6].  In addition, it appears that augmented 
insulin titration protocols require more skill on the part of providers who must now 
interpret a large amount of data [8], [19].  Given evidence that many providers will fail to 
correctly identify abnormal glucose patterns even after training, that 39% of individuals 
with T1DM are treated by general practitioners and that the general direction in US 
health care is toward lower cost solutions, the requirement of high provider skill appears 
to outweigh the other benefits of this approach as a general solution to the shortcomings 
of insulin titration [20], [21]. 
Closed-loop insulin delivery systems should in principle require less skill on the 
part of both patients and practitioners.  Similarly, issues of therapy adherence and 
accurate self-reports of blood glucose measurements as well as insulin and meal events 
are to a great degree unimportant in closed-loop control.  While, the development of more 
reliable continuous glucose monitors may be a barrier to commercial closed-loop insulin 
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systems [20], we are confident that industry along with artificial pancreas researchers can 
resolve all of the technical challenges facing closed-loop systems. 
However, the regulatory and economic challenges to closed-loop insulin delivery 
are considerable.  Because there are no predicate devices and because of the high 
potential for serious adverse events, an artificial pancreas will certainly be a Class III 
medical device.  A recent survey of medical device manufacturers found that the total 
time from prototype development to FDA approval of a Class III device is on average 9 
years [22].  In addition, those familiar with the artificial pancreas estimate that 
development costs will exceed $170 million [20].  Compounded by the limited adoption 
of insulin pumps in the US [23], the business case for the artificial pancreas is only 
compelling if market penetration significantly increases following the device’s FDA 
approval.  Further, reimbursement issues which have plagued other devices in the 
diabetes space may slow market penetration significantly [24]. 
Finally, decision support systems can have similar advantages and disadvantages 
depending on their design.  In the case of the Diabetes Insulin Guidance System, 
automated insulin titration, based on self-measured blood glucose, side-steps many of the 
challenges faced by augmentation of standard insulin titration protocols such as: long 
convergence times and high provider skill.  In addition, if this device can receive FDA 
approval through the 510k process, the total time to market could be as low as 4.5 years 
at a cost of $25 million [22].  This compares favorably to the development time and cost 
profile for the artificial pancreas which will require a PMA. 
However, the Diabetes Insulin Guidance system is designed to make the same 
titrations as a skilled physician [14].  As such, it may still be unable to provide good 
control for the many patients who struggle with the results of current titration protocols. 
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The framework developed in this work for calculating and personalizing insulin 
therapy parameters compares favorably with the above options.  Like the Diabetes Insulin 
Guidance System, our approach can provide titration recommendations very quickly, has 
no requirements for provider skill and based on private and informal conversations with 
some FDA officials, may qualify for approval through 510k process.  In addition, the 
results we have presented show that this approach can in provide good control for all 
individuals—ignoring of course the issue of wanton noncompliance with recommended 
therapeutic action.   
The main limitation at present appears to be the reliance of our approach of self-
reported meal and insulin logs.  As discussed earlier, individuals with diabetes can fail to 
maintain good or accurate logs of carbohydrate intake.  If this challenge could be 
resolved, using either smartphone based food logs [25] or smart insulin pens [26] the 
work of this dissertation could form the basis for a unique and highly differentiated 
solution to the problem of intensive insulin therapy in T1DM. 
COMMERCIAL AND ECONOMIC SIGNIFICANCE 
Manufacturers of glucose measurement devices are under tremendous pressure as 
a result of declining reimbursement and increasing price pressure from competitors [27].  
Further, increasing revenue and market share appears to require the development of new 
and highly differentiated technologies [27].  Finally, as a result of the current climate 
surrounding health care cost, medical device manufacturers are increasingly required to 
demonstrate comparative effectiveness to the FDA, insurance companies and health care 
providers [28].  The combination of these pressures has caused revenue growth for the 
entire industry to remain flat in the US and has led Roche, a major manufacturer of blood 
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glucose meters, to consider exiting the market despite having the most popular meter 
based on patient satisfaction [29], [30]. 
In light of these facts, the insulin therapy tools developed in this dissertation 
present a compelling commercial opportunity.  Firstly, recalling from Chapter 1 that 
universally good control of T1DM in the US could yield $4 billion in annual cost savings 
and that 66% of Americans with T1DM have poor glycemic control, we can calculate 
that the incremental value for bringing a single individual with T1DM from poor to good 
control is $6060 per year.  As the annual costs of blood glucose measurements supplies 
currently average $1,000 for an individual with T1DM, even a 10% success rate in 
moving individuals from poor to good control would create an additional $600 in value 
per person across a population of individuals with poorly controlled T1DM [31].  This 
seems almost certain to meet the requirements for comparative effectiveness for any 
concerned party.  Combined with the corresponding improvement in patient outcomes, 
this new device could very well easily lead to a shift in market share from competing 
manufacturers.   
FUTURE WORK 
While it is hoped that this work can be the basis for the next generation of insulin 
therapy tools, there are still many topics that require further work.  Some of these topics 
include: 
 
 Developing methods to improve parameter estimation techniques.  While 
the approach outlined in this work was adequate, there is certainly room 
for improvement.  Future investigators may wish to consider joint state 
and parameter estimation which has been used in studies of the artificial 
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pancreas [32].  Alternatively, “light” design of experiments, to design 
measurement protocols that can easily be performed at home but, which 
will provide more informative data may also be fruitful. 
 Determining when and how often insulin therapy should be adjusted.  It is 
known that numerous factors can affect insulin requirements on time 
scales as short as a single day or over several years.  Presently, insulin 
titration algorithms do not account for interday variability in insulin 
requirements.  However, using the tools developed in the present work, it 
is possible to estimate and personalize insulin therapy from as little as 
twelve hours of collected data.  The questions of if, when and how 
frequently updates to insulin therapy are necessary need to be answered. 
 Developing a system that makes the recording of accurate meal and 
insulin logs easy.  This system could be based on both manual and 
automated electronic recordings, as for example with a smartphone based 
meal log and a Bluetooth enabled insulin pen, though it is expected that 
minimizing user effort will produce more accurate logs.   
 Performing human studies to evaluate the performance of the derived 
insulin therapy parameters.  While we were able to show that the proposed 
insulin therapy framework can be used in the presence of significant 
model mismatch and for some sets of human data, the only way to truly 
validate our approach is to test it in humans. 
 Performing human or animal studies to assess the effect of variable 
perfusion on CGM performance.  As discussed, we believe that variations 
in capillary bed perfusion can adversely affect CGM performance.  
However, it is unclear whether the estimated magnitude of this issue is 
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correct.  In addition, other issues including sensor stability and 
manufacturing variations may presently be more important.  Some simple 
accuracy studies that account for variations in capillary bed perfusion can 
determine whether this is a major or minor challenge. 
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